

AD_____

REPORT NO. 68066

THE SYNTHESIS OF NEW ANTIMALARIAL DRUGS ANALOGS OF PANTOTHENIC ACID

FINAL REPORT
(combined with Annual Report 3)


RAJ K. RAZDAN
BARBARA A. ZITKO
AVINASH C. MEHTA

March 1969

Supported by
U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Washington, D. C. 20315

Contract No. DA-49-193-MD-2879

ARTHUR D. LITTLE, INC.
Cambridge, Massachusetts 02140




This document has been approved for public release and sale;
its distribution is unlimited

The findings in this report are not to be construed as an official
Department of the Army position unless so designated by other
authorized documents.

AD 685879

DISCLAIMER NOTICE



**THIS DOCUMENT IS BEST
QUALITY AVAILABLE. THE COPY
FURNISHED TO DTIC CONTAINED
A SIGNIFICANT NUMBER OF
PAGES WHICH DO NOT
REPRODUCE LEGIBLY.**

AD _____

Report No. 68066

The Synthesis of New Antimalarial Drugs
Analogues of Pantothenic Acid

Final Report
(combined with Annual Report 3)

Raj K. Razdan
Barbara A. Zitko
Avinash C. Mehta

March 1969

Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Washington, D. C. 20315

Contract No. DA-49-193-MD-2679

Arthur D. Little, Inc.
Cambridge, Massachusetts 02140

This document has been approved for public release
and sale; its distribution is unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated
by other authorized documents.

SUMMARY

During the three years of our work we have prepared and submitted for evaluation as potential antimalarials one hundred and eight compounds including repeat samples of which fifty are target compounds.

Except for WR 61467, AE 96096 and AF 14571 (pantoic acid derivatives of sulfadiazine, fanasil and kelfizina respectively) all of the target compounds so far tested in the Rane mice and bird screen have shown only marginal activity at best. The present synthetic program on antagonists of pantothenic acid was based on the demonstrated antimalarial activity of SN 14622 (WR 29,224) in avian malaria and more recently in Trager's in vitro screen, from the World War II program. Unfortunately, SN 14622 is completely inactive in the present WRAIR screens in mice (P. berghei), chicks (P. gallinaceum) and mosquitoes. In our opinion, the nonreproducibility of the activity of SN 14622, particularly in the present WRAIR chick screen is due to the different test procedure being used by Rane. We consider this screening procedure an improper one for our compounds. We suggest that the drug-diet method, used for testing SN 14622, should be repeated and used as a standard protocol method for these compounds. A few of our compounds were tested by Dr. Trager in his in vitro system with P. coatneyi in monkey erythrocyte suspension and he has found WR 54036 (an amide of pantoyltaurine) to be very active, much more so than SN 14622. We have been informed that on the basis of Dr. Trager's screen it has been selected for advanced screening in the monkey.

In the Rane screen in mice, WR 61467 has been found to be curative at 320 mg/kg and is active at 160 mg/kg. It is more active than sulfadiazine. Similarly, AE 96096 and AF 14571 are active at 40 mg/kg and 160 mg/kg respectively. We would recommend advanced biological evaluation of these compounds for (a) testing against resistant strains as possible candidates and (b) comparative evaluation against sulfas which are at present being administered in combination with pyrimethamine.

FOREWORD

In the middle of February 1966 work was started in our laboratories on the synthesis of "Analogues of Phenylpantothenone" and "Amides of Pantoyltaurine" as potential antimalarials under Contract DA-49-193-MD-2879. The first and the second annual reports were submitted in February of 1967 and 1968 respectively. The present final report covers the progress of work until March 1969, the termination date of the contract. The work carried out during this period was partly the subject of our proposals for renewal, dated July 24, 1967 and July 22, 1968.

Experimental details for only the compounds synthesized during the third year of our contract are given in this report. However, reference to the experimental details of the compounds synthesized in the previous two years may be obtained from the table of contents in this report.

Cumulative tables for the biological activity of all the compounds submitted so far to WRAIR for screening are included in this report.

Drs. T. R. Sweeney and B. Poon of the Department of Organic Chemistry, Walter Reed Army Institute of Research, continued to act as technical officers for this agency.

TABLE OF CONTENTS (Final Report)

	<u>page</u>
SUMMARY	3
FOREWORD	5
I. INTRODUCTION AND BACKGROUND	19
II. SYNTHESIS OF COMPOUNDS	
A. ANALOGS OF PHENYLPANTOTHENONE	23
B. AMIDES OF ω -METHYLPANTOYLTAURINE AND AMIDES OF PANTOYL-TAURINE	23
C. OTHER ANALOGS AND PHOSPHATE ESTERS	24
D. RELATED SULFONE DERIVATIVES	24
E. PANTOIC ACID DERIVATIVES	25
F. MISCELLANEOUS	25
III. BIOLOGICAL SCREENING DATA AND DISCUSSION OF RESULTS	27
IV. EXPERIMENTAL DETAILS	69
(+)-N-[2-[(2-QUINOLYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (AD 21709)	69
N-[2-[(3-QUINOLYL)SULFAMOYL]ETHYL]PHTHALIMIDE HYDROCHLORIDE (AD 21745)	70
2-AMINO-N-(3-QUINOLYL)ETHANESULFONAMIDE DIHYDROCHLORIDE (AD 21738)	70
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-ISOPROPYLBUTYRAMIDE (AE 96087)	71
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-[(4-CYCLOHEXYL)BUTYL]BUTYRAMIDE (AF 14606)	71
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-CYCLOHEXYLBUTYRAMIDE (AF 14580)	71
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-[3,3-(DIMETHYLAMINO)PROPYL]-BUTYRAMIDE (AF 14599)	72

TABLE OF CONTENTS (Final Report, cont'd)

	<u>page</u>
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-(2-TETRAHYDROPYRANYLMETHYL)- BUTYRAMIDE (AS 34783)	72
(-)-N-[2-(DIETHYLAMINO)ETHYL]2,4-DIHYDROXY-3,3-DIMETHYL- BUTYRAMIDE (AS 34809)	73
ε,ε-DIMETHYL-γ-BUTYROLACTONE	73
3,3-DIMETHYL-4-HYDROXY-N-(6-METHOXY-8-QUINOLYL)BUTYRAMIDE (AD 88937)	73
SODIUM ω-METHYLPANTOTHENATE (AE 86536)	74
DIBENZYLPHOSPHONATE	74
N[2-[(4-CHLOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3- DIMETHYLBUTYRAMIDE-4-DIBENZYLPHOSPHATE	74
N[2-[(4-CHLOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3- DIMETHYLBUTYRAMIDE-4-DIHYDROGENPHOSPHATE (AE 09655)	75
4,4-DIMETHYL-2-[(5-METHOXY-8-QUINOLYL)IMINO]TETRAHYDROFURAN- 3-OL (AD 21727)	75
2-BENZYLOXY-3,3-DIMETHYLBUTYRO-γ-LACTONE	76
2-BENZYLOXY-3,3-DIMETHYL-4-ACETOXYBUTYRAMIDE	76
2-BENZYLOXY-3,3-DIMETHYL-4-ACETOXY BUTYRIC ACID	77
2-BENZYLOXY-3,3-DIMETHYL-4-ACETOXY-N-[4-(2-PYRIMIDINYLAMINO- SULFONYL)PHENYL]BUTYRAMIDE (AD 88955)	77
4-ACETOXY-2-BENZYLOXY-3,3-DIMETHYL-4'-FLUROSULFONYLBUTYR- ANILIDE (AS 34792)	78
4-ACETOXY-2-BENZYLOXY-3,3-DIMETHYL-N-(1H,2,4-TRIAZOL-3- YL)BUTYRAMIDE (AS 34818)	78
4-ACETOXY-N-(2-BENZIMIDAZOLYL)-2-BENZYLOXY-3,3-DIMETHYL- BUTYRAMIDE (AT 14982)	79
2-BENZYLOXY-3,3-DIMETHYL-4-HYDROXY-N-[4-(2-PYRIMIDINYLAMINO- SULFONYL)PHENYL]BUTYRAMIDE (AD 88964)	80
2-BENZYLOXY-3,3-DIMETHYL-4-HYDROXY-N-(6-METHOXY-8-QUINOLYL)- BUTYRAMIDE (AE 86554)	80

TABLE OF CONTENTS (Final Report, cont'd)

	<u>page</u>
2-BENZYLOXY-3,3-DIMETHYL-4-HYDROXY-4'-[(3-METHOXY-2-PYRAZINYL)AMINOSULFONYL]BUTYRANILIDE (AF 14571)	81
2-BENZYLOXY-3,3-DIMETHYL-4'-[(5,6-DIMETHOXY-4-PYRIMIDINYL)-AMINOSULFONYL]-4-HYDROXYBUTYRANILIDE (AE 96096)	82
DIBENZYL p-BROMOANILINEPHOSPHONATE (AE 48983)	83
DIBENZYL p-METHOXYANILINEPHOSPHONATE (AE 48974)	83
DIBENZYL BENZYLAMINOPHOSPHONATE (AE 48965)	84
DIBENZYL N-CYCLOHEXYLPHOSPHORAMIDATE (AS 34774)	84
N'-2-(3,4,5,6-TETRAHYDOPYRIMIDINYL)SULFANILAMIDE (AE 86545)	85
TABLE 1. BIOLOGICAL RESULTS OF PHENYLPANTOTHENONES AND PANTOYL TAURINE DERIVATIVES	30
TABLE 2. BIOLOGICAL RESULTS OF RELATED SULFONE DERIVATIVES	46
TABLE 3. BIOLOGICAL RESULTS OF OTHER ANALOGS, PANTOIC ACID DERIVATIVES AND MISCELLANEOUS COMPOUNDS	52
TABLE 4. ACTIVITY OF COMPOUNDS IN TRAGER'S IN VITRO SCREEN	66
LITERATURE CITED	87
DISTRIBUTION LIST	89
DOCUMENT CONTROL DATA	91

TABLE OF CONTENTS (Annual Report I)

	<u>Page</u>
EXPERIMENTAL DETAILS	21
2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE	21
2,4-DIACETOXY-3,3-DIMETHYLVALERAMIDE	21
2,4-DIACETOXY-3,3-DIMETHYLVALERIC ACID	22
2,4-DIACETOXY-3,3-DIMETHYL-N-[3-OXO-3-(p-TOLYL)-1-PROPYL]VALERAMIDE (WR 40647)	23
2,4-DIACETOXY-3,3-DIMETHYL-N-[3-OXO-3-PHENYL-1-PROPYL]VALERAMIDE (WR 40646)	23
2,4-DIACETOXY-3,3-DIMETHYL-N-[3-(p-CHLOROPHENYL)-3-OXO-1-PROPYL]VALERAMIDE (WR 45491)	24
2-AMINO-N-PHENYLETHANESULFONAMIDE	25
2,4-DIHYDROXY-3,3-DIMETHYL-N-[2-(PHENYLSULFAMOYL)ETHYL]-VALERAMIDE (WR 35394)	25
N-[2-[(p-CHLOROPHENYL)SULFAMOYL]ETHYL]PHTHALIMIDE (WR 38441)	26
2-AMINO-N-(p-CHLOROPHENYL)ETHANESULFONAMIDE	27
N-[2-[(p-CHLOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 35393)	27
2-PHTHALIMIDO-N-(p-FLUOROPHENYL)ETHANESULFONAMIDE (WR 38443)	27
2-AMINO-N-(p-FLUOROPHENYL)ETHANESULFONAMIDE (WR 40645)	28
N-[2-[(p-FLUOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (ADL 14155-27)	28
N-[2-[(p-METHYLPHENYL)SULFAMOYL]ETHYL]PHTHALIMIDE (WR 38439)	29
2-AMINO-N-p-TOLYLETHANESULFONAMIDE	29

TABLE OF CONTENTS (Annual Report I, cont'd)

	<u>page</u>
2,4-DIHYDROXY-3,3-DIMETHYL-N-[2-[(p-METHYLPHENYL)-SULFAMOYLETHYL]VALERAMIDE (ADL 14155-78)	29
N-[2-[(p-METHOXYPHENYL)SULFAMOYL]ETHYL]PHTHALIMIDE (WR 38440)	30
2-AMINO-N-(p-METHOXYPHENYL)ETHANESULFONAMIDE	30
N-[2-[(p-METHOXYPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 52410)	30
N-[2-[(4-CHLORO-2,5-DIMETHOXYPHENYL)SULFAMOYL]ETHYL]-PHTHALIMIDE (WR 38442)	31
2-AMINO-N-(4-CHLORO-2,5-DIMETHOXYPHENYL)ETHANESULFONAMIDE (WR 40649)	32
N-[2-[(4-CHLORO-2,5-DIMETHOXYPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 40648)	32
N-[2-[(5-CHLORO-2,4-DIMETHOXYPHENYL)SULFAMOYL]ETHYL]-PHTHALIMIDE (WR 52405)	33
2-AMINO-N-(5-CHLORO-2,4-DIMETHOXYPHENYL)ETHANESULFONAMIDE (ADL 14143-47)	33
N-[2-[(5-CHLORO-2,4-DIMETHOXYPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 45492)	34
(-)-N-[2-[(p-FLUOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (ADL 14155-34)	35
(+)-N-[2-[(p-FLUOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (ADL 14155-36)	36
(+)-N-[2-[(4-CHLORO-2,5-DIMETHOXYPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (WR 52409)	36
(+)-N-[2-[(5-CHLORO-2,4-DIMETHOXYPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (WR 54035)	37
N-[2-[(2,5-DIFLUOROPHENYL)SULFAMOYL]ETHYL]PHTHALIMIDE (ADL 14421-31)	38
2-AMINO-N-(2,5-DIFLUOROPHENYL)ETHANESULFONAMIDE (ADL 14421-33)	38
(+)-N-[2-[(2,5-DIFLUOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (ADL 14155-44)	39

TABLE OF CONTENTS (Annual Report I, cont'd)

	<u>page</u>
N-[2-[(2,4-DIFLUOROPHENYL)SULFAMOYL]ETHYL]PHTHALIMIDE (ADL 14421-27)	39
2-AMINO-N-(2,4-DIFLUOROPHENYL)ETHANESULFOXAMIDE (ADL 14421-32)	40
(+)-N-[2-[(2,4-DIFLUOROPHENYL)SULFAMOYL]ETHYL]-2,4- DIIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (ADL 14155-45)	40
N-[2-[(6-METHOXY-8-QUINOLYL)SULFAMOYL]ETHYL]PHTHALIMIDE (WR 52408)	41
2-AMINO-N-(6-METHOXY-8-QUINOLYL)ETHANESULFOXAMIDE (WR 52112)	41
(+)-N-[2-[(6-METHOXY-8-QUINOLYL)SULFAMOYL]ETHYL]-2,4- DIIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (WR 54036)	42
N-[2-[(2-PYRAZINYL)SULFAMOYL]ETHYL]PHTHALIMIDE (ADL 14143-51)	43
2-AMINO-N-(2-PYRAZINYL)ETHANESULFOXAMIDE (WR 45823)	43
N-[2-[(6-METHOXY-3-PYRIDAZYL)SULFAMOYL]ETHYL]PHTHALIMIDE (ADL 14421-3)	43
2,4-DIACETOXY-3,3-DIMETHYL-N-[4-(2-PYRIMIDINYLAMINO- SULFONYL)PHENYL]VALERAMIDE (ADL 14155-43)	44

<u>TABLE OF CONTENTS (Annual Report II)</u>	<u>page</u>
EXPERIMENTAL DETAILS	25
N-[2-[(2,5-DIFLUOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 74110)	25
N-[2-[2,4-DIFLUOROPHENYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 74107)	26
N-[2-[(2-METHOXY-5-PYRIDYL)SULFAMOYL]ETHYL]PHTHALIMIDE (WR 74108)	26
2-AMINO-N-(2-METHOXY-5-PYRIDYL)ETHANESULFONAMIDE	27
N-[2-[(2-METHOXY-5-PYRIDYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (WR 76219)	27
N-[2-(2-PYRIMIDYLSULFAMOYL)ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (ADL 15056-8)	28
N-[2-(1-ADAMANTYLSULFAMOYL)ETHYL]PHTHALIMIDE (WR 74109)	29
2-AMINO-N-(1-ADAMANTYL)ETHANESULFONAMIDE	29
N-[2-(1-ADAMANTYLSULFAMOYL)ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (WR 87796)	30
N-[2-[(6-METHOXY-3-PYRIDAZYL)SULFAMOYL]ETHYL]PHTHALIMIDE (ADL 14421-3)	31
2-AMINO-N-(6-METHOXY-3-PYRIDAZYL)ETHANESULFONAMIDE (ADL 15337-20)	31
(+)-N-[2-[(6-METHOXY-3-PYRIDAZYL)SULFAMOYL]ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLBUTYRAMIDE (ADL 15337-24)	32
2-AMINOETHYL PHENYL SULFIDE HYDROCHLORIDE (WR 34649)	32
2,4-DIHYDROXY-3,3-DIMETHYL-N-[2-(PHENYLTHIO)ETHYL]-VALERAMIDE (ADL 15056-2)	33
2-AMINOETHYL p-CHLOROPHENYL SULFONE HYDROCHLORIDE (WR 28376)	33
N-[2-(p-CHLOROPHENYLSULFONYL)ETHYL]-2,4-DIHYDROXY-3,3-DIMETHYLVALERAMIDE (ADL 15056-3)	34
2-AMINOETHYL p-CHLOROPHENYL SULFIDE HYDROCHLORIDE (WR 37764)	35

TABLE OF CONTENTS (Annual Report II, cont'd)

	<u>page</u>
N-[2-(p-CHLOROPHENYLTHIO)ETHYL]-2,4-DIHYDROXY-3,3-DI-METHYLVALERAMIDE (WR 92073)	35
2-AMINOETHYL p-FLUOROPHENYL SULFIDE HYDROCHLORIDE (ADL 15056-12)	36
N-[2-(p-FLUOROPHENYLTHIO)ETHYL]-2,4-DIHYDROXY-3,3-DI-METHYLBUTYRAMIDE (ADL 15056-10)	36
2-AMINOETHYL p-FLUOROPHENYL SULFONE HYDROCHLORIDE (ADL 15119-8)	37
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-[2-(p-FLUOROPHENYL-SULFONYL)ETHYL]BUTYRAMIDE (ADL 15056-16)	37
2-AMINOETHYL p-FLUOROPHENYL SULFOXIDE HYDROCHLORIDE (WR 90191)	38
(+)-2,4-DIHYDROXY-3,3-DIMETHYL-N-[2-(p-FLUOROPHENYL-SULFINYL)ETHYL]BUTYRAMIDE (ADL 15056-17)	38
2-AMINOETHYL PHENYL SULFOXIDE HYDROCHLORIDE (WR 03735)	39
2-AMINOETHYL p-CHLOROPHENYL SULFOXIDE HYDROCHLORIDE (WR 87797)	39
2-AMINOETHYL PHENYL SULFONE HYDROCHLORIDE (WR 83969)	39
N-[2-(2-PYRIMIDYLSULFAMOYL)ETHYL]-4-HYDROXYBUTYRAMIDE (WR 90192)	40
4-HYDROXY-N-[2-(PHENYLTHIO)ETHYL]BUTYRAMIDE (WR 83971)	40
N-[2-(p-CHLOROPHENYLTHIO)ETHYL]-4-HYDROXYBUTYRAMIDE (WR 84131)	41
N-[2-(p-FLUOROPHENYLTHIO)ETHYL]-4-HYDROXYBUTYRAMIDE (WR 87798)	41
4-HYDROXY-N-[2-(PHENYLSULFINYL)ETHYL]BUTYRAMIDE (ADL 15056-14)	41
4-HYDROXY-N-[2-(p-PHENYLSULFONYL)ETHYL]BUTYRAMIDE (WR 84130)	42
N-[2-(p-CHLOROPHENYLSULFONYL)ETHYL]-4-HYDROXYBUTYRAMIDE (WR 77537)	42

TABLE OF CONTENTS (Annual Report II, cont'd)

	<u>page</u>
2,4-DIACETOXY-3,3-DIMETHYL-N-(6-METHOXY-8-QUINOLYL) VALERAMIDE (ADL 14155-46)	43
6-METHOXY-8-(TETRAHYDROFURAN-2-YLIDENEAMINO)QUINOLINE (ADL 15337-22)	44
DIBENZYL ANILINOPHOSPHONATE [DIBENZYL N-PHENYLPHOSPHOR- AMIDATE] (ADL 15458-1)	44
ATTEMPTED HYDROLYSIS OF WR 61467	44


I. INTRODUCTION AND BACKGROUND

The primary objective with which the U.S. Army Medical Research and Development Command had launched this research program, i.e., to find an effective antimalarial against resistant strains of *P. falciparum*, has not yet been achieved and vigorous research in the various aspects of malaria chemotherapy is being continued. However, encouraging results have been obtained on recent studies on volunteers infected with chloroquine-resistant *P. falciparum* with the use of a combination of sulfadiazine (or a longer acting sulfonamide) with pyrimethamine. Similarly a mixture of cycloguanil embonate and diacetyl derivative of diphenylsulfone (CI 564) has shown promising results.


Background

As a part of this program we have carried out the synthesis of analogs of pantothenic acid as potential antimalarials under Contract No. DA-49-193-MD-2879.

The biological rationale for the preparation of these compounds was based on the elegant work of Trager¹ who had shown that the addition of calcium pantothenate to an appropriate medium containing duck erythrocytes parasitized with *P. lophurae* increased the survival period of the parasite. Hence, the testing of pantothenic acid antagonists as potential antimalarials was initiated in the World War II program, and activity against *P. gallinaceum* and *P. lophurae* was found in phenylpantothenone (1, X = CO; R = H, Cl, etc.),^{2,3} amides of pantoyltaurine (1, X = SO₂NH; R = H, Cl, etc.),⁴ and in other related compounds (1, X = S, SO, SO₂; R = H, Cl).⁵




During the course of the program, we intended to synthesize compounds 2 and 3a as potential antimalarials in which the terminal -CH₂OH of the pantoyl part has been replaced by -CHCH-CH₃, a group which is known to produce potent pantothenic acid antagonists.⁶ In addition, we proposed to synthesize more examples in the series of amides of pantoyltaurine, 3b.



2


Analogs of phenylpantothenone




3

- a) ($\text{R}' = \text{CH}_3$), amides of ω -methylpantoyltaurine
 b) ($\text{R}' = \text{H}$), amides of pantoyltaurine

Recently, Dr. Trager⁷ has demonstrated very elegantly that the plasmodium in fact utilize Coenzyme A for their growth. Thus, the beneficial effect observed by him earlier of the addition of calcium pantothenate is an indirect one. We therefore proposed to synthesize simpler analogs of type 4 where only the pantoic acid part of the molecule [COCHOHC(CH₃)₂CH₂OH] has been changed. The important part of 4 is the terminal hydroxyl group. This is necessary because it will then be available for phosphorylation, etc., to be converted biosynthetically to the corresponding Coenzyme A derivatives, whereas this conversion would be blocked in the absence of the hydroxyl group.




4



5

In addition we proposed to synthesize a few examples of phosphate esters of 3b, e.g., 5 ($\text{R} = 4\text{-chlorophenyl}$). The preparation of these compounds would be, in a way, a step further toward the synthesis of the corresponding Coenzyme A analogs.


In view of the current interest in the antimalarial activity of the sulfone DPS against the resistant strain of *P. falciparum*, we had also proposed the synthesis of related sulfone derivatives of type 6.




6

$\text{X} = \text{S}, \text{SO}, \text{SO}_2; \text{R}' = \text{H}, \text{CH}_3$

Some pantoic acid derivatives were also proposed in which some of the known antimalarials (e.g., sulfadiazine, etc., and 8-aminoquinolines) would be synthesized with the added pantoic acid side chain (e.g., 7), and thus hopefully their metabolic pathway would be changed.⁸



We had also proposed the synthesis of compounds of type 8, some of which are known antipantothenates.⁹



8

Work carried out in the present program of synthesis of antipantothenates has led to an amide of pantoyltaurine^{8a} (WR 54036) which is very active in Trager's *in vitro* screen although inactive in the Rane screen. We have been informed that this compound has been selected for advanced screening in the monkey.¹⁰ Whereas a pantoic acid derivative^{8a} of sulfadiazine (WR 61467) has been found to be curative at 320 mg/kg, it is active at 160 mg/kg in the Rane screen and is inactive in Trager's *in vitro* screen. It is more active than sulfadiazine. Similarly pantoic acid derivatives of Fanasil (AE 96096) and Kelfizina (AF 14571) are active at 40 mg/kg and 160 mg/kg respectively in the Rane screen. Further data on these compounds are not yet available and are awaited with interest.


II. SYNTHESIS OF COMPOUNDS

A. Analogs of Phenylpantothenons (2)

Because of the extreme acid-base sensitivity of these compounds,^{8a p 7-11} the original scheme had to be abandoned and an alternative five-step synthesis was developed to give their diacetates. The three compounds submitted for biological testing have shown no activity in any of the malaria screens (Table IA).

B. Amides of ω -Methylpantoyltaurine (3a), and Amides of Pantoyltaurine (3b)


All but one of the 17 sulfonamides 9 originally suggested^{8a p 11-13} have been prepared. The sulfonamides 9 were synthesized as shown below and then were condensed with lactones 10 or 11 to give the target compounds 3a and 3b respectively. The lactone 11 condensed smoothly with the sulfonamides 9, but there was no reaction when lactone 10 was used. However, it was found that the condensation occurred when the sulfonamide 9 was used as its potassium salt.



Nearly all the suggested compounds^{8b p 6} were prepared. A total of 15 compounds including six target compounds have been submitted for biological evaluation. The various ω -methylpantoylsulfones, pantoylsulfones, and their precursor sulfides, sulfoxides, and sulfones which we have synthesized are listed in Table 2A, 2B, 2C, 2D and 2E respectively.

E. Pantoic Acid Derivatives (7)

Since the attempted hydrolysis of the diacetate groups in WR 61467 (7, R = Ac, R' = CH₃) failed under a variety of conditions, the original synthetic scheme was abandoned^{8b p 8-11} and an alternative synthesis as shown below was developed to give 16.



Derivatives of type 16 of sulfadiazine, Fanasil and Kelfizina have been prepared but in all cases the attempted debenzoylation to give the target compound 7 (R = R' = H) have failed. The heterocyclic nucleus of the sulfas is reduced instead. However, compounds of type 16 are very important from the biological activity point of view, as they have the necessary terminal hydroxyl group (see p. 20).

Three compounds, WR 61467, AE 96096 and AF 14571, are active in the Rane screen. The biological data on a number of compounds in this series are not yet available.


The list of pantoic acid derivatives we have synthesized are listed in Table 3B.

F. Miscellaneous


A few substituted dibenzyl anilinophosphonates were prepared by allowing the amine to react with dibenzyl phosphochloridate in refluxing benzene. They are listed in Table 3C.

III. BIOLOGICAL SCREENING DATA AND DISCUSSION OF RESULTS


As discussed earlier, the present synthetic program on antagonists of pantothenic acid was based on the demonstrated antimalarial activity in avian malaria of phenylpantothenones and amides of pantooyl-taurine. The most active compound, i.e., SN 14622 (WR 29,224) was reported to be ten times as active as quinine when tested against blood-induced *P. gallinaceum* infection in the chick.^{4,11,12} More recently, Trager has shown the *in vitro* inhibitory effect of SN 14622 on *P. lophurae*, *P. coatneyi*, and *P. falciparum* developing intracellularly.⁷ Unfortunately, SN 14622 is not being picked up¹³ in the present WRAIR screens in mice (*P. berghei*), chicks (*P. gallinaceum*) and mosquitoes. Our target compounds so far tested, except WR 61467, AE 96096 and AF 14571, have shown marginal activity at best in mice and chicks. However, a few of our compounds were tested by Dr. Trager in his *in vitro* screen.^{8b} He has found WR 35393 to be as active as SN 14622 and WR 54036 much more active than SN 14622 (Table 4a and 4b).




SN 14622 (WR 29,224)
(+ isomer)



WR 35393



WR 54036 (+ isomer)



WR 61467

The non reproducibility of the activity of SN 14622 in the present WRAIR chick screen is both disappointing and puzzling. To us it seems the difference lies in the test procedure. In the present screen the drug is administered to the chick either subcutaneously or per os immediately after infection as a single dose, whereas in the World War II program the drug-diet method was used¹⁴ and the administration of the drug was begun one day before infection and was continued for four days after infection. Perhaps in the present test method the lack of activity is due to insufficient levels of the drug in the blood. We suggest that the method used for testing SN 14622 (see reference 14) should be repeated and used as a standard protocol method for these compounds. We have been informed, however, that WR 54036, which is most





active in Trager's screen, has been selected for advanced screening in the monkey.¹⁰ In view of the difference in activity in the two chick screens, we would recommend that due consideration be given to having adequate drug levels in the blood in the test procedure to be used in the monkey screen. This whole question has been brought to the attention of WRAIR.

Among pantoic acid derivatives WR 61467 is curative in mice (Rane screen) at 320 mg/kg and is active at 160 mg/kg. It is more active than sulfadiazine. It is inactive in Trager's in vitro screen (Table 4b). This latter inactivity of WR 61467 is perhaps due to the presence of the acetate group which is not hydrolyzed in the in vitro system and thus is not available for phosphorylation, etc. With the present data it is difficult to assess whether its activity is due to hydrolysis in vivo to sulfadiazine. Some light may be thrown on this aspect when some results

from the Trager screen become available on compound 16 ($R' = \text{---} \langle \text{C}_6\text{H}_4 \rangle \text{---SO}_2\text{NH} \langle \text{C}_4\text{H}_3\text{N}_2 \rangle$), which has a free terminal hydroxyl group.

Similarly AE 96096 (Fanasil derivative) and AF 14571 (Kelfizina derivative) are active at 40 mg/kg and 160 mg/kg respectively in the Rane screen. Further data on these compounds is not yet available. We would recommend advanced biological evaluation of these for (a) testing against resistant strains as possible candidate compounds and (b) comparison with sulfas which are at present being administered in combination with pyrimethamine. These compounds will be most interesting if their activity is based on something different than hydrolysis in vivo to the corresponding sulfas.

TABLE 1. Biological Results of Phenylpantothenones and Pantoyltaurine Derivatives

<u>Identification</u>	<u>Compound</u>	<u>Dose</u> <u>mg/kg</u>	<u>Mice</u>			<u>Toxic</u> <u>Deaths</u>
			<u>Survival Time, days</u>			
			<u>Mean</u> <u>treated</u>	<u>Mean</u> <u>control</u>	<u>change</u>	
<u>A. Analogs of Phenylpantothenone</u>						
	$R = \text{CH}_2\text{CH}_2\text{NHCOCH} \begin{array}{c} \text{CH}_3 \\ \\ \text{C} \\ \\ \text{OAc} \end{array} \text{---} \begin{array}{c} \text{CH} \\ \\ \text{CH}_3 \end{array} \text{---} \text{CH}_3$					
ADL 14155-32 WR 40646		20 80 320	6.2 6.7 6.1	6.2 6.2 6.2	0.0 0.0 0.0	00 00 00
ADL 14155-25 WR 40647		10 40 160	6.2 6.4 6.4	6.2 6.2 6.2	0.0 0.2 0.2	00 00 00
ADL 14155-35 WR 45491		10 40 160	6.4 6.4 6.6	6.1 6.1 6.1	0.3 0.3 0.5	00 00 00
<u>B. Amides of α-Methylpantoyltaurine</u>						
	$R = \text{CH}_2\text{CH}_2\text{NHCOCH} \begin{array}{c} \text{CH}_3 \\ \\ \text{C} \\ \\ \text{OH} \end{array} \text{---} \begin{array}{c} \text{CH} \\ \\ \text{CH}_3 \end{array} \text{---} \text{CH}_3$					
ADL 14155-22 WR 35394		40 160 640	6.8 7.0 8.2	6.5 6.5 6.5	0.3 0.5 1.7	00 00 00
ADL 14155-26 WR 35393		40 160 640	7.6 8.4 9.2	6.5 6.5 6.5	1.1 1.9 2.7	00 00 00

Dose mg/kg	Bird			Toxic Deaths	Mosquito				Synthesis cn Page
	Survival Time, days				Dose % conc	Percent			
	Mean	change	Toxic Deaths			Toxic Deaths	Abnormal Oocysts	Suppression	
treated	control			oocysts	sporozoites				
									I (23)*
									I (23)
60	5.0	4.2	0.8	00					
120	5.0	4.2	0.8	00					I (24)
240	5.0	4.2	0.8	00					
120	4.0	3.6	0.4	00					
240	4.0	3.6	0.4	00					I (25)
480	4.0	3.6	0.4	00					
120	4.0	3.5	0.5	00					I (27)

*Annual Report I, p. 23



TABLE 1. (contd)

Identification	Compound	Mice			Toxic Deaths	
		Dose mg/kg	Survival Time, days			
			Mean treated	Mean control		change
ADL 14155-27 WR 35395						
ADL 14155-28 WR 35392		40 160 640	6.4 6.6 7.0	6.1 6.1 6.1	0.3 0.5 0.9	00 00 03
ADL 14155-29 WR 52410						
ADL 14155-30 WR 40648		40 160 640	6.6 6.6 7.0	6.2 6.2 6.2	0.4 0.4 0.8	00 00 02
ADL 14155-31A WR 45492		40 160 640	6.4 6.8 6.8	6.1 6.1 6.1	0.3 0.7 0.7	00 00 00
ADL 14155-47 WR 74107		40 160 640	6.2 6.4 6.8	6.2 6.2 6.2	- 0.2 0.6	00 00 00
ADL 14155-48 WR 74110		40 160 640	6.2 (7.0) 6.2 (7.0) 6.4 (7.4)	6.1 (6.2) 6.1 (6.2) 6.1 (6.2)	0.1 (0.8) 0.1 (0.8) 0.3 (1.2)	00 00 00


Dose mg/kg	Bird				Mosquito					Synthesis on Page
	Survival Time, days			Toxic Deaths	Dose % conc	Percent			Suppression oocysts sporozoites	
	treated	control	change			Toxic Deaths	Abnormal Oocysts			
										I (28)
120	4.0	3.6	0.4	00						
240	4.0	3.6	0.4	00						I (29)
480	4.0	3.6	0.4	00						
										I (30)
										I (32)
										I (34)
120	4.0	3.6	0.4	00						
240	4.0	3.6	0.4	00						II (26)*
480	4.0	3.6	0.4	00						
120	4.0	3.6	0.4	00	0.1	17	0	0	0	II (25)

*Annual Report II, p. 26


TABLE 1. (contd)

Identification	Compound	Dose mg/kg	Mice			Toxic Deaths
			Survival Time, days			
			treated	control	change	
ADL 14155-49 WR 76219		40 160 640	6.2 6.2 6.2	6.1 6.1 6.1	0.1 0.1 0.1	00 00 00
ADL 15056-8 WR 91946		40 160 640	6.4 6.6 6.6	6.4 6.4 6.4	0.0 0.2 0.2	00 00 00


C. Amides of Pantoyltaurine




ADL 14155-34
WR 44247




ADL 14155-36
WR 44323



ADL 14155-37
WR 52409








ADL 14155-38A
WR 54035









Dose mg/kg	Bird				Mosquito					Synthesis on Page
	Survival Time, days			Toxic Deaths	Dose % conc	Toxic Deaths	Percent			
	Mean treated	Mean control	change				Abnormal Oocysts	Suppression oocysts sporozoites		
										II (27)
60	3.8	3.2	0.6	00						
120	3.8	3.2	0.6	00						II (28)
240	3.8	3.2	0.6	00						
										I (35)
										I (36)
120	4.0	3.5	0.5	00						I (36)
					0.001	9	-	-	-	
					0.01	11	-	-	-	I (37)
					0.1	9	0	0	0	

TABLE 1. (contd)

<u>Identification</u>	<u>Compound</u>	<u>Dose</u> <u>mg/kg</u>	<u>Mice</u>			<u>Toxic</u> <u>Deaths</u>
			<u>Survival Time, days</u>			
			<u>Mean</u> <u>treated</u>	<u>Mean</u> <u>control</u>	<u>change</u>	
ADL 14155-44 WR 66440	 <chem>Fc1cc(F)cc(NHSO2R)c1</chem> dextro(+)					
ADL 14155-45 WR 66439	 <chem>Fc1cc(F)cc(NHSO2R)c1</chem> dextro(+)					
ADL 14155-39 WR 54036	 <chem>COc1ccc2nc(NHSO2R)ccc12</chem> dextro(+)	40 160 640	6.8 6.8 7.0	6.1 6.1 6.1	0.7 0.7 0.9	00 00 00
ADL 15056-4 WR 87796	 <chem>C1CC2(C1)CCN2NHSO2R</chem>	40 160 640	6.2 6.2 6.2	6.1 6.1 6.1	0.1 0.1 0.1	00 00 00
ADL 15337-24 AC 64236	 <chem>COc1ccc(N=N)cc1NHSO2R</chem> dextro(+)	40 160 640	6.8 6.8 7.0	6.4 6.4 6.4	0.4 0.4 0.6	00 00 00
ADL 15337-35 AD 21709	 <chem>c1ccncc1NHSO2R</chem> dextro(+)	10 40 60	6.4 6.6 6.6	6.1 6.1 6.1	0.3 0.5 0.5	00 00 00






ng/kg	Bird			Toxic Deaths	Dose % conc	Mosquito			Synthesis on Page	
	Survival Time, days					Toxic Deaths	Percent			Suppression oocysts sporozoites
	Mean treated	Mean control	change				Abnormal Oocysts			
									I (39)	
									I (40)	
					0.001	6	-	-	-	I (42)
					0.01	9	-	-	-	
					0.1	31	-	-	-	
					0.1	0	0	0	0	II (30)
										II (32)
10	4.0	3.9	0.1	00						69
20	4.0	3.9	0.1	00						
40	4.0	3.9	0.1	00						
80	4.0	3.9	0.1	00						
160	4.0	3.9	0.1	00						
320	4.0	3.9	0.1	00						

TABLE 1. (contd)

Identification	Compound	Dose mg/kg	Mice			Toxic Deaths
			Survival Time, days			
			Mean treated	Mean control	change	
<u>D. 2-Amino-N-Substituted Sulfonamide</u>						
ADL 14143-29 WR 40645		40	6.2	6.2	0.0	00
		160	6.4	6.2	0.2	00
		640	6.4	6.2	0.2	00
ADL 14143-52 WR 40649		40	6.2	6.2	0.0	00
		160	7.0	6.2	0.8	02
		640	0.0	6.2	0.0	95
ADL 14143-47 WR 61463		40	6.2	6.2	-	00
		160	6.2	6.2	-	00
		640	6.2	6.2	-	00
ADL 14421-33 WR 61466		20	6.4	6.2	0.2	00
		80	6.8	6.2	0.6	00
		320	6.8	6.2	0.6	00
ADL 14221-32 WR 61462		40	6.2	6.2	-	00
		160	6.2	6.2	-	00
		640	6.2	6.2	-	00
ADL 14421-12 WR 52112		40	6.4	6.2	0.2	00
		160	7.0	6.2	0.8	03
		640	-	6.2	-	05
ADL 14421-9 WR 45823		40	7.0	6.1	0.9	00
		160	7.2	6.1	1.1	00
		640	7.4	6.1	1.3	00

Bird				Mosquito					Synthesis on Page
Dose mg/kg	Survival Time, days			Dose % conc	Toxic Deaths	Abnormal Oocysts	Percent Suppression		
	treated	control	change				oocysts	sporozoites	
									I (28)
									I (32)
									i (33)
									I (38)
									I (40)
				0.1	57	0	0	0	I (41)
									I (43)

TABLE 1. (contd)

Identification	Compound	Dose mg/kg	Mice			Toxic Deaths
			Survival Time, days			
			treated	control	charge	
			Mean			
ADL 15537-20		40	7.0	6.4	0.6	00
AC 64245		160	7.2	6.4	0.8	00
		640	7.6	6.4	1.2	00
ADL 15337-27						
AD 21736						
<u>E. Phthalimides</u>						
						
ADL 14143-49A		40	7.2	6.5	0.7	00
WR 35396		160	7.6	6.5	1.1	00
		640	8.4	6.5	1.9	00
ADL 14143-49B		20	6.2	6.1	0.1	00
WR 38441		80	6.4	6.1	0.3	00
		320	6.4	6.1	0.3	00
ADL 14143-27		20	6.2	6.1	0.1	00
WR 38443		80	6.2	6.1	0.1	00
		320	7.0	6.1	0.9	02
ADL 14143-50A		20	6.8	6.1	0.7	00
WR 38439		80	6.8	6.1	0.7	00
		320	7.0	6.1	0.9	00

Bird				Mesquito					Synthesis on Page
Dose mg/kg	Survival Time, days			Dose % conc	Toxic Deaths	Abnormal Oocysts	Percent		
	Mean treated	control	change				Suppression oocysts	sporozoites	

II (31)

70








I (25)

I (26)

I (27)





I (29)

TABLE 1. (contd)

Identification	Compound	Dose mg/kg	Mice			Toxic Deaths
			Survival Time, days			
			Mean treated	control	change	
ADL 14143-50B WR 38440		20	6.6	6.1	0.5	00
		80	6.6	6.1	0.5	00
		320	7.2	6.1	1.1	00
ADL 14143-42 WR 38442		40	6.2	6.1	0.1	00
		160	6.2	6.1	0.1	00
		640	7.0	6.1	0.9	03
ADL 14143-43 WR 52405						
ADL 14421-31 WR 61464		40	6.2	6.2	-	00
		160	6.6	6.2	0.4	00
		640	6.6	6.2	0.4	00
ADL 14421-27 WR 61465		40	6.4	6.2	0.2	00
		160	6.4	6.2	0.2	00
		640	6.4	6.2	0.2	00
ADL 14421-4 WR 52408		40	6.4	6.1	0.3	00
		160	6.6	6.1	0.5	00
		640	7.4	6.1	1.3	00
ADL 14143-51 WR 44011						

Bird				Mosquito					Synthesis on Page	
Dose mg/kg	Survival Time, days			Toxic Deaths	Dose % conc	Percent				
	Mean treated	Mean control	change			Toxic Deaths	Abnormal Oocysts	Suppression oocysts sporozoites		
									I (30)	
									I (31)	
									I (33)	
									I (38)	
									I (39)	
					0.001	6	-	-	-	I (41)
					0.01	9	-	-	-	
					0.1	6	0	0	0	
										I (43)

TABLE 1. (contd)

<u>Identification</u>	<u>Compound</u>	Mice				<u>Toxic Deaths</u>
		<u>Dose mg/kg</u>	<u>Survival Time, days</u>			
			<u>Mean treated</u>	<u>control</u>	<u>change</u>	
ADL 14421-3 WR 44313						
ADL 14421-19 WR 74108		40 160 640	6.2 6.2 6.2	6.2 6.2 6.2	- - -	00 00 00
ADL 14421-43 WR 74109		20 80 320	6.2 6.2 6.2	6.2 6.2 6.2	- - -	00 00 00
ADL 15337-26 AD 21745						

Dose mg/kg	Bird				Mosquito				Synthesis on Page	
	Survival Time, days			Toxic Deaths	Dose % conc	Percent		Suppression		
	treated	control	change			Toxic Deaths	Abnormal Oocysts	oocysts		sporozoites

120	4.0	3.6	0.4	00					
-----	-----	-----	-----	----	--	--	--	--	--




I (43)

II (26)

II (29)



70

TABLE 2. Biological Results of Related Sulfone Derivatives



<u>Identification</u>	<u>Compound</u>	<u>Dose</u> <u>mg/kg</u>	<u>Mice</u>			<u>Toxic</u> <u>Deaths</u>
			<u>Survival Time, days</u>			
			<u>treated</u>	<u>control</u>	<u>change</u>	
<u>A. ω-Methylpantoylsulfones</u>						
	$R = \text{CH}_2\text{CH}_2\text{NHCOCH} \begin{array}{c} \\ \text{CH}_3 \\ \\ \text{C} \\ \\ \text{OH} \end{array} \begin{array}{c} \\ \text{CH}_3 \\ \\ \text{C} \\ \\ \text{OH} \end{array} \text{CH}-\text{CH}_3$					
ADL 15056-2 WR 83970						
ADL 15056-3 WR 91945		20 80 320	6.8 6.8 7.0	6.4 6.4 6.4	0.4 0.4 0.6	00 00 00
ADL 15056-9 WR 92073		40 160	6.6 6.8	6.2 6.2	0.4 0.4	00 00
<u>B. Pantoylsulfones</u>						
	$R = \text{CH}_2\text{CH}_2\text{NHCOCH} \begin{array}{c} \\ \text{CH}_3 \\ \\ \text{C} \\ \\ \text{OH} \end{array} \begin{array}{c} \\ \text{CH}_3 \\ \\ \text{C} \\ \\ \text{OH} \end{array} \text{CH}_2$					
ADL 15056-10 WR 91947	 S-R dextro(+)	40 160 640	6.4 6.4 6.6	6.4 6.4 6.4	0.0 0.0 0.2	00 00 00

Bird					Mosquito				Synthesis on Page
Dose g/kg	Survival Time, days			Toxic Deaths	Dose % conc	Toxic Deaths	Percent		
	treated	Mean control	change				Abnormal Oocysts	Suppression oocysts sporozoites	
									II (33)
60	4.0	3.2	0.8	00					
120	4.0	3.2	0.8	00					II (34)
240	4.0	3.2	0.8	00					
30	4.0	3.3	0.7	00					
60	4.0	3.3	0.7	00					II (35)
120	4.0	3.3	0.7	00					
60	3.8	3.2	0.6	00					
120	4.0	3.2	0.8	00					II (36)
240	4.0	3.2	0.8	00					

TABLE 2. (contd)





<u>Identification</u>	<u>Compound</u>	<u>Dose</u> <u>mg/kg</u>	<u>Mice</u>			<u>Toxic</u> <u>Deaths</u>
			<u>Survival Time, days</u>			
			<u>Mean</u> <u>treated</u>	<u>control</u>	<u>change</u>	
ADL 15056-16 AC 64227	 -SO ₂ -R dextro(+)	40 160 640	7.0 7.0 7.4	6.4 6.4 6.4	0.6 0.6 1.0	00 00 00
ADL 15056-17 AC 64183	 -SO-R dextro(+)	20 80 320	7.0 7.4 7.4	6.4 6.4 6.4	0.6 1.0 1.0	00 00 00

C. Sulfides ·HCl

ADL 14421-62 WR 34649	 -SCH ₂ CH ₂ NH ₂	40 160 640	7.2 7.5 -	6.1 6.1 6.1	1.1 1.4 -	00 01 05
ADL 14421-61 WR 37764	 -SCH ₂ CH ₂ NH ₂	40 160 640	6.4 6.6 7.0	6.1 6.1 6.1	0.3 0.5 0.9	00 00 02
ADL 15056-12 WR 91948	 -SCH ₂ CH ₂ NH ₂					

Dose mg/kg	Bird			Toxic Deaths	Dose % conc	Mosquito			Synthesis on Page	
	Survival Time, days					Toxic Deaths	Abnormal Oocysts	Suppression		
	Mean treated	Mean control	change					oocysts		sporozoites
					0.1	0	0	0	0	II (37)
										II (38)
					0.1	6	0	0	0	II (32)
					0.1	0	0	0	0	II (35)
										II (36)




TABLE 2. (contd)

Identification	Compound	Dose mg/kg	Mice			Toxic Deaths
			Survival Time, days			
			treated	control	charge	
<u>D. Sulfoxides ·HCl</u>						
ADL 15119-7 WR 03735		40	6.2	6.2	-	00
		160	6.4	6.2	0.2	00
		640	6.4	6.2	0.2	00
ADL 15119-1 WR 87797		40	6.2	6.2	-	00
		160	6.2	6.2	-	00
		640	6.2	6.2	-	00
ADL 15119-10 WR 90191		40	6.6	6.2	0.4	00
		160	7.0	6.2	0.8	00
		640	7.0	6.2	0.8	00
<u>E. Sulfones ·HCl</u>						
ADL 14421-65 WR 83969		40	6.2	6.2	-	00
		160	6.4	6.2	0.2	00
		640	6.4	6.2	0.2	00
ADL 14421-63 WR 28376		40	6.4	6.1	0.3	00
		160	6.4	6.1	0.3	00
		640	7.0	6.1	0.9	03
ADL 15119-8 AC 64209		40	6.8	6.4	0.4	00
		160	6.8	6.4	0.4	00
		640	7.0	6.4	0.6	00

Bird				Mosquito					Synthesis on Page
Dose mg/kg	Survival Time, days			Dose % conc	Toxic Deaths	Abnormal Oocysts	Suppression		
	Mean treated	control	change				Toxic Deaths	sporozoites	
				0.1	51	0	25	50*	II (39)
				0.1	3	0	0	0	
				0.1	14	0	0	0	II (39)
				0.1	0	0	0	0	II (38)
				0.1	9	0	25	0	II (39)
									II (33)
				0.1	3	0	0	0	II (37)

*Partial Sporozoite Suppression







TABLE 3. Biological Results of Other Analogs, Pantoic Acid Derivatives and Miscellaneous Compounds

<u>Identification</u>	<u>Compound</u>	<u>Dose</u> <u>mg/kg</u>	<u>Mice</u>			<u>Toxic</u> <u>Deaths</u>
			<u>Survival Time, days</u>			
			<u>Mean</u> <u>treated</u>	<u>Mean</u> <u>control</u>	<u>change</u>	
<u>A. Other Analogs</u>						
R = CH ₂ CH ₂ NHCOCH ₂ CH ₂ CH ₂ OH						
ADL 15056-7 WR 90192		40 160 640	6.2 6.4 6.4	6.2 6.2 6.2	- 0.2 0.2	00 00 00
ADL 15056-1 WR 83971		40 160 640	6.6 6.6 6.8	6.2 6.2 6.2	0.4 0.4 0.6	00 00 00
ADL 14421-75 WR 84131		40 160 640	6.4 6.6 6.8	6.2 6.2 6.2	0.2 0.4 0.6	00 00 00
ADL 15119-11 WR 87798		40 160 640	5.2 6.4 6.4	6.2 6.2 6.2	- 0.2 0.2	00 00 00
ADL 15056-14 AC 64254		40 160 640	7.0 7.2 7.6	6.4 6.4 6.4	0.6 0.8 1.2	00 00 00
ADL 15119-6 WR 84130		40 160 640	6.2 6.2 6.2	6.2 6.2 6.2	- - -	00 00 00

Dose mg/kg	Bird				Mosquito					Synthesis on Page
	Survival Time, days			Toxic Deaths	Dose % conc	Toxic Deaths	Percent Abnormal Oocysts	Suppression		
	treated	control	change					oocysts	sporozoites	
60	4.0	3.7	0.3	00	0.1	3	0	0	0	II (40)
60	4.0	3.7	0.3	00						II (40)
60	4.0	3.7	0.3	00						
120	4.0	3.7	0.3	00	0.1	9	0	0	0	II (41)
240	4.0	3.7	0.3	00						
					0.1	17	0	0	0	II (41)
					0.1	3	0	0	25*	
					0.1	17	0	25	0	II (41)
60	4.0	3.7	0.3	00						
120	4.0	3.7	0.3	00	0.1	29	0	0	0	II (42)
240	4.0	3.7	0.3	00						



*Partial Sporozoite Suppression

TABLE 3. (contd)

Identification	Compound	Dose μg/kg	Mice			Toxic Deaths
			Survival Time, days			
			Mean treated	control	change	
ADL 14155-52 WR 77537		40 160 640	6.2 6.2 6.2	6.2 6.2 6.2	- - -	00 00 00
	$R' = \begin{array}{c} \text{CH}_3 \\ \\ \text{COCH}-\text{C}-\text{CH}_2\text{OH} \\ \quad \\ \text{OH} \quad \text{CH}_3 \end{array}$					
ADL 15056-20 AE 96087		20 80 320	6.2 6.2 6.2	6.2 6.2 6.2	0.0 0.0 0.0	00 00 00
15056-21 AF 14606		10 40 160	6.2 6.4 6.4	6.1 6.1 6.1	0.1 0.3 0.3	00 00 00
15337-67 AF 14580		20 80 320	6.2 6.2 6.2	6.1 6.1 6.1	0.1 0.1 0.1	00 00 00
15337-68 AF 14599		20 80 320	6.2 6.4 6.4	6.1 6.1 6.1	0.1 0.3 0.3	00 00 00
15337-69 AS 34783						




Dose mg/kg	Bird				Mosquito					Synthesis on Page
	Survival Time, days			Toxic Deaths	Dose % conc	Toxic Deaths	Percent Abnormal Oocysts	Suppression		
	treated	control	change					oocysts	sporozoites	
30	4.0	3.6	0.4	00						II (42)
60	4.0	3.6	0.4	00						
120	4.0	3.6	0.4	00						
7.5	4.0	3.3	0.7	00						
15	4.0	3.3	0.7	00						
30	4.0	3.3	0.7	00	0.1	34	0	25	0	71
60	4.0	3.3	0.7	00						
120	4.0	3.3	0.7	00						
240	4.0	3.3	0.7	00						
										71
					0.1	57	0	0	0	71
					0.1	57	0	0	0	72
										72

TABLE 3. (contd)

Identification	Compound	Mice				Toxic Deaths
		Dose mg/kg	Survival Time, days			
			Mean treated	control	change	
15337-71 AS 34809	$\begin{array}{c} \text{C}_2\text{H}_5 \\ \diagdown \\ \text{NCH}_2\text{CH}_2\text{NH-R}' \\ \diagup \\ \text{C}_2\text{H}_5 \end{array}$ levo(-)					
15056-19 AD 88937		10 40 160	6.2 6.4 6.4	6.1 6.1 6.1	0.1 0.3 0.3	00 00 00
15337-42 AE 86536	$\begin{array}{c} \text{CH}_3 \\ \\ \text{CH}_3-\text{CH}-\text{C}-\text{CH}-\text{CONHCH}_2\text{CH}_2\text{COONa} \\ \quad \quad \\ \text{OH} \quad \text{CH}_3 \quad \text{OH} \end{array}$					
15458-8R ₂ AE 09655						







Dose mg/kg	Bird				Mosquito				Synthesis on Page
	Survival Time, days			Toxic Deaths	Dose % conc	Percent			
	Mean treated	control	change			Toxic Deaths	Abnormal Oocysts	Suppression oocysts sporozoites	
10	3.8	3.3	0.0	00					73
20	3.8	3.8	0.0	00					
40	4.0	3.8	0.2	00					73
80	4.0	3.8	0.2	00					
160	4.0	3.8	0.2	00					
320	4.0	3.8	0.2	00					
10	4.0	3.0	1.0	00					
20	3.8	3.0	0.8	00					
40	4.0	3.0	1.0	00					
80	4.0	3.0	1.0	00					74
160	4.0	3.0	1.0	00					
320	4.0	3.0	1.0	00					
2.5	3.0	3.0	0.0	00					
5	3.0	3.0	0.0	00					
10	3.0	3.0	0.0	00					
20	3.0	3.0	0.0	00					75
40	3.0	3.0	0.0	00					
80	3.4	3.0	0.4	00					

TABLE 3. (contd)

Identification	Compound	Mice				Toxic Deaths	
		Dose mg/kg	Survival Time, days				
			Mean treated	Mean control	change		
B. Pantoic Acid Derivatives							
ADL 15337-22		40	7.0	6.4	0.6	00	
AC 64192		160	7.0	6.4	0.6	00	
		640	7.0	6.4	0.6	00	
ADL 15337-32							
AD 21727							
	$R^2 = \begin{array}{c} \text{CH}_3 \\ \\ \text{COCH}-\text{C}-\text{CH}-\text{CH}_3 \\ \quad \quad \\ \text{OAc} \quad \text{CH}_3 \quad \text{OAc} \end{array}$						
ADL 14155-43							
WR 61467							
		<u>cures</u>					
		00	20	8.6	6.2	2.4	00
		00	40	9.4	6.2	3.2	00
		00	80	10.6	6.2	4.4	00
		00	160	14.0	6.2	7.8	00
		04	320	-	6.2	-	00
		04	640	-	6.2	-	01




Dose mg/kg	Bird			Toxic Deaths	Dose % conc	Mosquito			Synthesis on Page	
	Survival Time, days					Toxic Deaths	Abnormal Oocysts	Percent		
	treated	control	change					Suppression oocysts		sprozoites
					0.01	6	0	0	0	II (44)
					0.1	100				
										75
					0.0001	6	-	-	-	
					0.01	6	-	-	-	I (44)
					0.1	3	0	0	0	

TABLE 3. (contd)


Identification	Compound	Bird			Toxic Deaths	
		Dose mg/kg	Survival Time, days			
			Mean treated	control	change	
ADL 14155-46 WR 68826						
	$R^3 = \begin{array}{c} \text{CH}_3 \\ \\ \text{COCH}-\text{C}-\text{CH}_2 \\ \quad \\ \text{C}_6\text{H}_5\text{CH}_2\text{O} \quad \text{CH}_3 \quad \text{OAc} \end{array}$					
15337-51 AD 88955						
15337-70 AS 34792						
15337-72 AS 34818						
15897-2 AT 14982						
	$R^4 = \begin{array}{c} \text{CH}_3 \\ \\ \text{COCH}-\text{C}-\text{CH}_2\text{OH} \\ \quad \\ \text{C}_6\text{H}_5\text{CH}_2\text{O} \quad \text{CH}_3 \end{array}$					
15337-53 AD 88964		10 40 160	6.4 6.4 7.6	6.1 6.1 6.1	0.3 0.3 1.5	00 00 00


Dose mg/kg	Bird			Toxic Deaths	Mosquito					Synthesis on Page
	Survival Time, days				Dose % conc	Toxic Deaths	Abnormal Oocysts	Suppression		
	Mean treated	control	change					oocysts	sporozoites	
					0.001	20	-	-	-	II (43)
					0.01	0	-	-	-	
					0.1	46	0	25	0	
										77
										78
										78
										79
10	3.6	3.0	0.6	00						
20	3.8	3.0	0.8	00						
40	3.8	3.0	0.8	00						
80	3.4	3.0	0.4	00						
160	4.0	3.0	1.0	00						80
320	4.0	3.0	1.0	00						


TABLE 3. (contd)

Identification	Compound	Dose mg/kg	Mice			Toxic Deaths
			Survival Time, days			
			treated	control	change	
15337-60 AE 86554		20 80 320	6.4 6.6 6.6	6.2 6.2 6.2	0.2 0.4 0.4	00 00 00
15337-62 AF 14571		10 20 40 80 160 320	6.6 7.2 8.2 8.8 11.7 12.0	6.1 6.1 6.1 6.1 6.1 6.1	0.5 1.1 2.1 2.7 5.6 5.9	00 00 00 00 00 00
15337-63 AE 96096		20 40 80 160 320 640	9.8 15.5 15.7 - - -	6.1 6.1 6.1 6.1 6.1 6.1	3.7 9.4 9.6 - - -	00 00 00 00 00 00

3. Miscellaneous






ADL 15458-1		40 160 640	7.2 7.2 7.6	6.4 6.4 6.4	0.8 0.8 1.2	00 00 00
AC 64218						

ADL 15458-12 AE 48983						
--------------------------	---	--	--	--	--	--

Dose ng/kg	Bird			Toxic Deaths	Mosquito					Synthesis on Page
	Survival Time, days				Dose % conc	Toxic Deaths	Percent Abnormal Oocysts	Suppression		
	Mean treated	control	change					oocysts	sporozoites	
										80
										81
15	4.0	3.3	0.7	00						
30	4.0	3.3	0.7	00						
60	4.0	3.3	0.7	00	0.1	29	0	0	0	82
120	4.0	3.3	0.7	00						
240	4.0	3.3	0.7	00						
480	4.0	3.3	0.7	00						
10	3.6	3.3	0.3	00						
20	3.6	3.3	0.3	00						
40	3.6	3.3	0.3	00	0.1	3	0	0	0	II (44)
80	3.6	3.3	0.3	00						
160	4.0	3.3	0.7	00						
320	4.0	3.3	0.7	00						

TABLE 3. (contd)

<u>Identification</u>	<u>Compound</u>	<u>Mice</u>			<u>Toxic Deaths</u>
		<u>Dose mg/kg</u>	<u>Survival Time, days</u>		
			<u>mean treated</u>	<u>control change</u>	
15458-13 AE 48974					
15458-14 AE 48965					
15458-18 AS 34774					
15337-58 AE 86545					

Dose mg/kg	Bird			Toxic Deaths	Mosquito			Synthesis on Page	
	Survival Time, days				Dose % conc	Percent			Suppression oocysts sporozoites
	Mean treated	control	change			Toxic Deaths	Abnormal Oocysts		
10	3.6	3.3	0.3	00				84	
20	3.6	3.3	0.3	00					
40	3.6	3.3	0.3	00				85	
80	3.6	3.3	0.3	00					
160	3.6	3.3	0.3	00					
320	3.6	3.3	0.3	00					

85

86

Table 4a

Activity of Compounds in Trager's In Vitro Screen^a

Flask No.	Addition	Conc µg/ml	Parasites per 10,000 red cells ^b						
			Day 1					Abnormal ^c	Total
R	Tr	ES	LS	G					
1	H ₂ O		0	2	6	34	1	1	44
2	H ₂ O		0	2	1	27	0	1	31
3	WR	75	0	11	11	3	2	10	37
4	54036A	75	0	14	1	0	0	10	25
5	WR	25	0	4	9	36	0	0	49
6	54036A	25	1	9	12	27	0	0	49
7	WR	75	0	12	6	9	0	7	34
8	35393B	75	0	8	7	10	0	-	32
9	SN	75	0	4	4	8	0	7	23
10	14622	75	0	3	13	29	0	9	54
11	WR	25	0	2	2	38	2	1	45
12	68826A	25	0	2	2	42	0	1	48

- a) W. Trager, Rockefeller University, Personal Communication.
- b) At time 0 count was 45 to 55 per 10,000 red cells, of which nearly all were young uninucleate trophozoites.
R = rings; Tr = 1-nucleate; ES = Binucleate forms; LS = Forms with 3 or more nuclei; G = Gametocytes.
- c) The abnormal parasites were chiefly rather large 1-nucleate forms with a large nucleus, one or more large pigment masses and some small vacuoles. They still showed a good differential stain.

Flask No.	Addition	Conc µg/ml	Day 1 Total ^d	Parasites per 10,000 red cells						
				Day 2					Abnormal	Total
R	Tr	ES	LS	G						
1	H ₂ O		31	43	11	0	2	1	0	57
2	H ₂ O		12	66	4	0	2	0	0	72
3	WR	75	9	0	0	0	0	0	5	5
4	54036A	75	17	0	0	0	0	0	4	4
5	WR	25	18	0	1	1	1	0	1	4
6	54036A	25	8	0	1	1	1	0	1	4
7	WR	75	12	4	0	1	1	0	4	10
8	35393B	75	16	0	1	0	3	0	6	10
9	SN	75	25	1	1	0	5	0	2	9
10	14622	75	4	0	0	0	2	0	3	5
11	WR	25	13	32	1	0	4	0	0	37
12	68826A	25	10	43	0	0	5	1	1	50

- d) On day 1, after centrifugation and resuspension of the cells in fresh medium, they received, per flask, 0.3 ml of fresh uninfected monkey blood thereby reducing the count of parasites per 10,000 red cells to about one-third to one-half its previous value.

Table 4b

Flask No.	Addition	Conc µg/ml	Parasites per 10,000 red cells ^e						
			Day 1					Total	
			R	Tr	ES	LS	G	Abnormal ^f	Normal
1			0	5	10	9	0	0	24
2	H ₂ O		0	4	13	8	0	0	25
3	WR	37	0	12	15	2	0	3	29
4	54036A		0	9	14	0	0	3	26
5	WR	75	0	8	4	0	0	7	12
6	54036A		0	6	4	0	0	9	10
7	WR	75	0	4	10	12	0	2	26
8	61467		0	3	7	13	2	3	25
9	WR	150	0	6	13	12	1	1	32
10	61467		0	11	22	10	4	1	47

e) At time 0 count was 36 to 42 per 10,000 red cells of which 10 to 17 were rings and the rest young uninucleate trophozoites.

R = rings; Tr = 1-nucleate; ES = 2-3 nuclei; LS = Forms with 4 or more nuclei; G = gametocytes.

f) Abnormalities were of several types, still clearly recognizable as parasites, usually with 1 nucleus.

Flask No.	Addition	Conc µg/ml	Parasites per 10,000 red cells							
			Day 1 ^d Total	Day 2					Total	
			R	Tr	ES	LS	G	Abnormal	Normal	
1			11	19	1	2	8	4	0	34
2	H ₂ O		8	22	0	0	6	5	3	33
3	WR	37	22	0	4	0	1	0	8	5
4	54036A		13	0	4	1	0	2	5	7
5	WR	75	8	1	1	0	0	0	4	2
6	54036A		4	0	1	0	0	0	5	1
7	WR	75	14	19	0	0	5	1	3	25
8	61467		12	10	1	0	6	3	1	20
9	WR	150	15	14	0	1	7	2	2	24
10	61467		18	16	0	0	7	1	4	24

IV. EXPERIMENTAL DETAILS

Melting points are uncorrected. Analyses were by Spang Micro-analytical Laboratories, Ann Arbor, Mich., and G. Braith Microanalytical Laboratories, Knoxville, Tenn. NMR spectra were obtained on a Varian, Model A-60 spectrometer. Peak positions are reported in terms of parts per million from tetramethylsilane. Ultraviolet absorption spectra were determined on a Beckman, DK-1A recording spectrophotometer. Infrared spectra were recorded on a Perkin-Elmer 237 spectrometer.

Copies of all spectra are on file at Arthur D. Little, Inc., and are available on request.

(+)-N-[2-[(2-Pyrazinyl)sulfamoyl]ethyl]-2,4-dihydroxy-3,3-dimethylbutyramide (AD 21709)

3.0 g (0.015 mole) of 2-amino-N-(2-pyrazinyl)ethanesulfonamide^{8a} p 43 was suspended in absolute alcohol and an alcohol solution containing one equivalent of freshly prepared potassium ethoxide was added. After refluxing for one hour, the solution was cooled and ethanol was removed on the vacuum rotary evaporator. After drying for two hours *in vacuo*, the potassium salt was powdered and combined with 2.2 g (0.017 mole) of (-)- α -hydroxy- δ , δ -dimethyl- γ -butyrolactone (Pfaltz and Bauer, Inc.). The mixture was heated at 115-120° for 24 hr. The residue was dissolved in a small amount of water and neutralized with dilute (15%) hydrochloric acid. This solution was evaporated to dryness and the residue extracted with absolute alcohol. The extract was evaporated to a brown gum. Trituration with ethanol gave 0.8 g of beige solid which was removed by filtration. The filtrate was concentrated and chromatographed through a column of silicic acid (100 mesh) using increasing quantities of methanol in chloroform. The fraction eluted with 25% methanol/chloroform contained the amide (0.6 g). This fraction was combined with the beige solid and recrystallized several times from ethanol/ether. Total yield was 1.3 g (26%) of white powder, $[\alpha]_D^{23} +16.9$ (ethanol), mp 162-165°. Anal. Calcd for C₁₂H₂₀N₄O₅S: C, 43.37; H, 5.06; N, 16.83. Found: C, 43.46; H, 5.83; N, 16.51.

The amide showed ultraviolet absorption bands at $\lambda_{\text{max}}^{\text{EtOH}}$ 297 m μ (log ϵ 3.54), 282 m μ (log ϵ 3.58), 245 m μ (log ϵ 3.79) and 218 m μ (log ϵ 3.99) and infrared bands (KBr) at 3400, 1645 and 1055 cm⁻¹.

A 1.3 g sample (15337-35) was submitted on April 22, 1968, for testing in the WRAIR malaria screen.

N-[2-[(3-Quinuclidinyl)sulfamoyl]ethyl]phthalimide Hydrochloride (AD 21745)

To 20.0 g (0.1 mole) of 3-aminoquinuclidine dihydrochloride suspended in chloroform was added with vigorous stirring an aqueous solution of 8.0 g (0.2 mole) of sodium hydroxide. The chloroform layer was separated, washed, dried and evaporated to give 11.0 g of 3-aminoquinuclidine (beige solid - very hygroscopic). Finely powdered 2-phthalimidoethanesulfonyl chloride (24.0 g, 0.088 mole) was added slowly and with stirring to a pyridine solution (75 ml) of 3-aminoquinuclidine (11.0 g, 0.088 mole). The reaction mixture was cooled and stirred vigorously during the addition and for another one hour. During this time the orange solution changes to a solid yellow-white mass. Ethyl ether was added and the mixture stirred at room temperature for one hour. The mixture was filtered and the solid was washed well with ether. After drying in vacuo, the solid was recrystallized first from water and then methanol to give 17.0 g (45%) white powder, mp 258-260°. Anal. Calcd for $C_{17}H_{21}N_3O_4S \cdot HCl$; C, 51.06; H, 5.54; N, 10.51. Found: C, 50.95; H, 5.48; N, 10.46.

Nmr spectrum (DMSO-d₆) 2.0 (multiplet, area 4), 3.33 (multiplet, 8), 3.9 (multiplet, 4), 7.98 (singlet, 4), 8.15 (broad, 1 D₂O exchange).

A 0.5 g sample (15337-26) was submitted on April 22, 1968, for testing in the WRAIR malaria screen.

2-Amino-N-(3-quinuclidinyl)ethanesulfonamide Dihydrochloride (AD 21736)

To 17.0 g (0.024 mole) of N-[2-[(3-quinuclidinyl)sulfamoyl]ethyl]phthalimide hydrochloride suspended in hot absolute ethanol was added one equivalent of freshly prepared potassium ethoxide solution. After filtration, the solution was adjusted to 125 ml of 95% ethanol and 2.45 g (0.042 mole) of hydrazine hydrate (85%) was added. The mixture was refluxed with stirring for three hours and the excess ethanol was removed on the rotary evaporator. The residue was suspended in approximately 75 ml of warm water and made acid to Congo red with dilute (15%) hydrochloric acid. After stirring for fifteen minutes, the mixture was cooled and filtered. The water was evaporated to give a clear viscous oil which solidified upon trituration with methanol. This solid recrystallized from methanol-water as 9.0 g of white granules, mp 247-249°. Anal. Calcd for $C_9H_{19}N_3O_2S \cdot 2HCl$: C, 35.30; H, 6.91; N, 13.72. Found: C, 35.41; H, 6.92; N, 13.73.

A 0.5 g sample (15337-27) was submitted on April 22, 1968, for testing in the WRAIR malaria screen.

(+)-2,4-Dihydroxy-3,3-dimethyl-N-isopropylbutyramide (AE 96087)

4.9 g (0.03 mole) of (-)- α -hydroxy- β,β -dimethyl- γ -butyrolactone was heated with excess isopropylamine at 110° for 4 hr with occasional stirring. A solution of resulting clear viscous liquid in a small quantity of ethyl acetate was chromatographed through a column of silicic acid (100 mesh) with the same solvent. The fraction which showed one spot in tlc and had bulk of the material was collected. It was washed with 1N hydrochloric acid solution followed by sodium bicarbonate solution and finally with water. After drying the solvent was removed to leave 3.6 g (64%) of a golden gum $[\alpha]_D^{20} +47.4^\circ$ (ethanol).

Anal. Calcd for $C_{11}H_{19}NO_3$: C, 57.11; H, 10.12; N, 7.4. Found: C, 56.89; H, 10.13; N, 7.33.

It showed infrared bands (KBr) at 3350 and 1640 cm^{-1} . A 2.9 g sample (15056-20) was submitted on August 30, 1968 for testing in the WRAIR malaria screen.

(+)-2,4-Dihydroxy-3,3-dimethyl-N-[(4-cyclohexyl)butyl]butyramide (AF 14606)

2.6 g (0.02 mole) of (-)- α -hydroxy- β,β -dimethyl- γ -butyrolactone was combined with 3.50 g (0.0225 mole) of 4-cyclohexylbutylamine and heated at 100° for three hours. The viscous residue was dissolved in chloroform and chromatographed using silicic acid (100 mesh). The desired product was eluted with 5% methanol/chloroform, and evaporation of solvents gave 3.8 g of a colorless oil. Analysis indicated trace amounts of lactone present. The compound was purified by dissolving in ethyl acetate and washing with dilute hydrochloric acid followed by sodium bicarbonate solution and water. After drying over sodium sulfate the solvent was evaporated, and the colorless residue was dissolved in a small quantity of ethyl ether. Petroleum ether was added and the mixture was cooled until the compound separated into an oily layer. This process was repeated an additional two times. Total yield was 3.5 g (64%) of colorless gum with $[\alpha]_D^{23} +40.1$ (95% ethanol).

Anal. Calcd for $C_{17}H_{27}NO_3$: C, 67.33; H, 10.95; N, 4.91. Found: C, 67.03; H, 11.09; N, 4.79.

The amide showed infrared bands at 3380 and 1650 cm^{-1} .

A 2.5 g sample (15056-21) was submitted on September 30, 1968, for testing in the WRAIR malaria screen.

(+)-2,4-Dihydroxy-3,3-dimethyl-N-cyclohexylbutyramide (AF 14587)

3.25 g (0.025 mole) of (-)- α -hydroxy- β,β -dimethyl- γ -butyrolactone was combined with 2.50 g (0.025 mole) of cyclohexylamine and heated at 110-120° for four hours with occasional stirring. The reaction mixture crystallizes upon cooling. Two recrystallizations from

methylene chloride/petroleum ether gave 4.5 g (76%) of white crystals, mp 100-102°, $[\alpha]_D^{20} +46.2^\circ$ (95% ethanol).
Anal. Calcd for $C_{12}H_{23}NO_3$: C, 61.85; H, 10.11; N, 6.11. Found: C, 62.62; H, 10.15; N, 6.07.

The amide showed ultraviolet bands at 3370, 3250 and 1640 cm^{-1} .

A 2.5 g sample (15337-67) was submitted on September 30, 1968, for testing in the WRAIR malaria screen.

(+)-2,4-Dihydroxy-3,3-dimethyl-N-[3,3(dimethylamino)propyl]butyramide (AF 14599)

3.25 g (0.025 mole) of (-)- α -hydroxy- β,β -dimethyl- γ -butyrolactone was heated with excess 3-dimethylaminopropylamine (3.5 g, 0.027 mole) at 110-120° for 3 hours with occasional stirring. The viscous residue was triturated several times with petroleum ether. The washings were decanted and the colorless gum was dissolved in ether. With cooling and scratching, a white crystalline solid appeared. Recrystallization was difficult and the compound was purified as an oil. The solid was dissolved in benzene and petroleum ether was added until formation of a distinct oily layer. After decanting the solvents, the viscous oil was dissolved in ether and crystallized with cooling. The compound was obtained as 1.4 g (24%) white crystals, mp 66.5-71°.

Anal. Calcd for $C_{11}H_{24}N_2O_3$: C, 56.87; H, 10.41; N, 12.05. Found: C, 56.59; H, 10.32; N, 11.91.

The amide showed infrared bands at 3400, 3300 and 1630 cm^{-1} .

A 1.3 g sample (15337-68) was submitted on September 30, 1968, for testing in the WRAIR malaria screen.

(+)-2,4-Dihydroxy-3,3-dimethyl-N-(2-tetrahydropyranylmethyl)butyramide (AS 34783)

3.25 g (0.025 mole) of (-)- α -hydroxy- β,β -dimethyl- γ -butyrolactone was heated with 2.90 g (0.025 mole) of 2-aminomethyltetrahydropyran at 110-120° for 4 hours with occasional stirring. After cooling, the residue was dissolved in a small quantity of chloroform and passed through a column of Florisil (60-100 mesh). The compound was eluted with 5% ethanol/chloroform. Evaporation of the solvents left a colorless viscous residue which was dissolved in ether. Petroleum ether was added until the material separated out as an oily layer. The solvents were decanted, and the whole procedure repeated an additional two times. Tlc showed one spot, and the sample was dried to give 2.25 g (37%) of colorless oil, $[\alpha]_D^{23} +44.1$ (95% ethanol).

Anal. Calcd for $C_{12}H_{23}NO_4$: C, 58.75; H, 9.45; N, 5.71. Found: C, 58.81; H, 9.62; N, 5.79.

The amide had infrared bands at 3400 (broad) and 1650 cm^{-1} .

A 2.1 g sample (15337-69) was submitted on December 2, 1968, for testing in the WRAIR malaria screen.

(-)-N-[2-(Diethylamino)ethyl]2,4-dihydroxy-3,3-dimethylbutyramide (AS 34809)

2.64 g (0.02 mole) of (-)- α -hydroxy- δ,δ -dimethyl- γ -butyrolactone was heated with 2.32 g (0.02 mole) of N,N-diethylethylenediamine at 110° for 4 hours. The clear viscous residue was dissolved in chloroform and passed through a column of Florisil (60-100 mesh). The fraction eluted with 10% methanol/chloroform contained the desired compound. The solvents were evaporated to leave a viscous oil, which was dissolved in a small amount of ether. Petroleum ether was added until the compound separated and a distinct layer formed. The solvents were decanted and the whole procedure again repeated. After drying there remained 1.45 g (29%) of colorless oil, $[\alpha]_D^{25}$ -36.2 (95% ethanol).

Anal. Calcd for $\text{C}_{12}\text{H}_{26}\text{N}_2\text{O}_3 \cdot 1/2 \text{H}_2\text{O}$: C, 56.45; H, 10.57; N, 10.97.
Found: C, 56.57; H, 10.78; N, 10.97. The amide showed infrared bands at 3350 and 1645 cm^{-1} .

A 1.4 g sample (15337-71) was submitted on December 2, 1968, for testing in the WRAIR malaria screen.

δ,δ -Dimethyl- γ -butyrolactone

It was prepared according to a literature procedure¹⁵ as a light yellow solid, mp 55-57° (lit. 55-57°) in 27% yield.

3,3-Dimethyl-4-hydroxy-N-(6-methoxy-8-quinolyl)butyramide (AD 88937)

3.75 g (.013 mole) of 2-amino-N-(6-methoxy-8-quinolyl)ethanesulfonamide was suspended in absolute ethanol and on alcohol solution containing one equivalent of freshly prepared potassium ethoxide was added. After refluxing for 1 hr, the solution was cooled and ethanol was removed on a vacuum rotary evaporator. The potassium salt thus obtained was further dried for 2 hr in vacuo. The solid was powdered and heated with 1.65 g (.014 mole) of δ,δ -dimethyl- γ -butyrolactone at 115° for 4 hr with occasional stirring. The viscous residue was suspended in water and neutralized with dilute hydrochloric acid. The resulting mixture was extracted with ethyl acetate, washed, dried and evaporated to leave a gum. This gum was chromatographed through a column of silicic acid (100 mesh) and eluted with 50:50 ethyl acetate/benzene followed by ethyl acetate alone. On elution with ethyl acetate a major fraction was collected which on concentration in vacuo left a gum. It solidified on tituration with ether. The solid was filtered and recrystallized from chloroform/ether/petroleum ether mixture to give 1.3 g (26%) of a yellow solid, mp 123-125°.

Anal. Calcd for $C_{12}H_{25}N_3O_5S$: C, 54.67; H, 6.37; N, 10.63. Found: C, 54.86; H, 6.20; N, 10.55.

The amide showed ultraviolet absorption bands at $\lambda_{\text{max}}^{\text{EtOH}}$ 330 m μ ($\log \epsilon$ 3.59), 242 m μ ($\log \epsilon$ 4.55) and infrared bands (KBr) at 3380, 1625, 1300, 1140 cm^{-1} .

A 1.25 g sample (15056-19) was submitted on May 29, 1968, for testing in the WRAIR malaria screen.

Sodium α -Methylpantothenate^{6b} (AE 86536)

A mixture of 2.22 g of the sodium salt of β -Alanine (0.02 moles) and 3.16 g (0.022 moles) of freshly distilled α -methylpantolactone was heated at 110-120° for 3 hours. The product was dissolved in 150 ml of isopropanol; the solution was cooled and filtered to remove a small quantity of white solid. The volume of isopropanol was reduced to 50 ml and the remaining solution was stored at 0°C for several weeks. During this time solid was removed by filtration and the mother liquor was again stored in the cold. Total yield of white solid was 1.0 g (19%), mp 147-150° (lit. 160-161.5°). Attempts at purification (crystallization, chromatography) failed and the compound remained slightly impure.

Anal. Calcd for $C_{10}H_{16}O_5NNa$: C, 47.05; H, 7.11; N, 5.49. Found: C, 45.75; H, 6.81; N, 5.73.

The amide showed in infrared absorption band (KBr) at 1625 cm^{-1} .

A 0.9 g sample (15337-42) was submitted on July 30, 1968, for testing in the WRAIR malaria screen.

Dibenzylphosphonate

It was prepared according to a literature procedure.¹⁶

N[α -[(4-Chlorophenyl)sulfonyl]ethyl]-2,4-dihydroxy-3,3-dimethylbutyramide-4-dibenzylphosphate

1.82 g (0.005 mole) of WR 29,224 (SN 14622) was dissolved in 50 ml of anhydrous pyridine and the solution cooled in a dry ice bath. A solution of dibenzylchlorophosphoridate¹⁷ (from 2.62 g, 0.01 mole of dibenzylphosphonate and 1.35 g of N-chlorosuccinimide) in 30 ml of dry benzene was then added and the solution was thawed and rapidly frozen in dry ice bath and left at that temperature for 18 hr. Water (10 ml) was added and the reaction mixture left at room temperature for 2 hr. Pyridine, water and benzene from the reaction mixture were removed on the rotary evaporator under reduced pressure at a bath temperature less

than 35°. The residual oily liquid was extracted with ethyl acetate. The extract was washed three times each with 2N sulfuric acid, 10% sodium bicarbonate and saturated sodium sulfate and finally dried over sodium sulfate. Removal of the solvent on the rotary evaporator under reduced pressure at less than 35° bath temperature gave a syrupy residue. The residue was treated with a mixture of ether and benzene (1:1) and the solvent removed on the rotary evaporator. This process was repeated three times. Finally the last traces of the solvent were removed directly on the vacuum pump when the residue started becoming a fluffy solid. This, when macerated with dry ether, changed into a white crystalline solid (1.05 g), mp 117-119° with early sintering at 80-85°. Tlc in $\text{CHCl}_3/\text{MeOH}::33:66$ showed a single spot.

Anal. Calcd for $\text{C}_{22}\text{H}_{34}\text{ClN}_2\text{O}_5\text{PS}$: C, 53.80; H, 5.45; N, 4.48. Found: C, 53.85; H, 5.42; N, 4.39.

It showed infrared bands (KBr) at 3340, 1645, 1485, 1330, 1242, 1140, 1020 cm^{-1} . Nmr spectrum (CCl_4) 0.87, 1.0 (singlet, 6), 3.24, 3.7 (broad, 6), 3.97 (singlet, 1), 4.57 (broad, D_2O exchange, 1), 4.97, 5.11 (singlet, 4), 7.3 (multiplet, 14), 7.74 (broad, D_2O exchange, 1), 8.96 (broad, D_2O exchange, 1).

N[2-[(4-Chlorophenyl)sulfonyl]ethyl]-2,4-dihydroxy-3,3-dimethylbutyramide-4-dihydrogenphosphate (AE 09655)

The above dibenzylphosphate (1 g) was dissolved in some methanol and the hydrogenation flask flushed with nitrogen before adding 2 g of 10% Pd-C. The mixture was hydrogenated at atmospheric pressure. Theoretical amount of hydrogen was absorbed in an hour. The hydrogenated mixture was filtered and the filtrate concentrated on the rotary evaporator at less than 50° bath temperature. Tlc of the residual mixture (460 mg) indicated the presence of three compounds. Using preparative tlc (silica gel C, 1 mm; 10% MeOH in CHCl_3 as developer) a pure compound (260 mg) was obtained.

Anal. Calcd for $\text{C}_{14}\text{H}_{22}\text{ClN}_2\text{O}_5\text{PS}$: C, 37.80; H, 4.95; N, 6.30. Found: C, 37.43; H, 5.35; N, 6.28.

It showed infrared bands (KBr) at 3400-3250, 1650, 1490, 1325, 1140, 1030 cm^{-1} .

A 1.0 g sample of 15456-82₂ (95% pure on the basis of elemental and mass spectrum analyses) was submitted on June 10, 1968, for testing in the WRAIR malaria screen.

4,4-Dimethyl-2-[(6-methoxy-8-quinolyl)imino]tetrahydrofuran-3-ol (AD 21727)

Three grams (0.017 mole) of 8-amino-6-methoxyquinoline and 4.5 g (0.035 mole) of (-)- α -hydroxy- β , β -dimethyl- γ -butyrolactone (Pfaltz and Bauer, Inc.) were combined and heated in a sealed tube at 25° for

24 hr. The contents of the tube were dissolved in chloroform and filtered. The chloroform was evaporated and a large quantity of ethyl ether added. Filtration removed additional polymeric material. A small amount (0.4 g) of impure product was obtained after concentration of the filtrate and trituration with ethyl acetate. The solid was purified by column chromatography (silicic acid - 100 mesh) using ethyl acetate, chloroform and ethanol. The fractions eluted with ethyl acetate and chloroform contained starting material and some dark-colored impurities. Evaporation of the ethanol fraction and recrystallization from methylene chloride/ether gave 0.1 g (3%) beige powder, mp 202-204°C. Chromatography was attempted on the filtrate from the ethyl acetate trituration but no additional material could be obtained.

Anal. Calcd for $C_{16}H_{18}N_2O_3$: C, 67.11; H, 6.34; N, 9.79. Found: C, 67.16; H, 6.25; N, 9.70.

Nmr spectrum ($DMSO-d_6$): 1.11, 1.2 (singlets, area 6), 3.51, 3.84 (doublet, 2), 3.9 (singlet, 3), 4.08 (singlet, 1), 5.61 (broad, 1 D_2O exchange), 7.34 (multiplet, 3), 8.28 (doublet, 1), 8.7 (multiplet, 1).

The compound showed ultraviolet absorption at λ_{max}^{EtOH} 332 m μ (log ϵ 3.72), 283 m μ (log ϵ 3.55) and 230 m μ (log ϵ 4.53) and a characteristic infrared band (KBr) at 1705 cm^{-1} .

A 0.1 g sample (15337-32) was submitted on April 22, 1968, for testing in the WRAIR malaria screen.

\pm 2-Benzyl-oxy-3,3-dimethylbutyro- γ -lactone¹⁸

(*)Pantolactone (11, 130 g, 1 mole) was added to a solution of 23 g of sodium in 400 ml of absolute alcohol and the mixture stirred at room temperature for 1.5 hr. Alcohol was removed on the rotary evaporator and the residual solid macerated with dry ether, filtered as quickly as possible and dried for 48 hr in a vacuum desiccator.

106 g of the dried sodium salt was suspended in 500 ml of dry xylene and 95 ml of benzyl chloride was added. The mixture was refluxed with stirring for 2 hr, cooled and diluted with water. The organic layer was separated, washed first with 150 ml of 2N H_2SO_4 and then with water and finally dried over anhydrous sodium sulphate. Removal of xylene on the rotary evaporator under reduced pressure gave 118 g of a yellow oily residue which was used directly without further purification in the next step.

\pm 2-Benzyl-oxy-3,3-dimethyl-4-acetoxybutyramide

A mixture of above benzyl-oxy-lactone (66 g) and 150 ml of liquid ammonia was left at room temperature in a steel bomb for 18 hr. The reaction mixture which had solidified to a hard cake was broken into small pieces which were macerated with dry ether and filtered as quickly

as possible. The solid material (44 g) was transferred immediately to a 500 ml R.B. flask and 200 ml of pyridine followed by 75 ml of acetic anhydride were added and the reaction mixture stirred at room temperature for 24 hr. Pyridine and acetic anhydride were removed under reduced pressure and to the residual oily liquid excess of ether was added. The ether extract was washed successively with 2N H₂SO₄, aq NaHCO₃ and water and finally dried over anhydrous sodium sulphate. Ether was removed first on the rotary evaporator and finally on the vacuum pump when 31 g of a crystalline solid, mp 61-66°, was obtained. It was recrystallized from ether/pet. ether to give colorless crystals, mp 64-66°. Anal. Calcd for C₁₅H₂₁NO₄ requires: C, 64.49; H, 7.58; N, 5.01. Found: C, 64.55; H, 7.68; N, 15.13.

It showed bands (Nujol mull) at 3410, 3275, 1730, 1675 cm⁻¹. Nmr spectrum (CDCl₃): 1.03, 1.05 (singlet, 6), 1.97 (singlet, 3), 3.75 (singlet, 1), 3.87, 4.12 (J = 11 cps, 2), 4.39, 4.68 (J = 12 cps, 2), 6.48 (broad, D₂O exchange, 2), 7.35 (singlet, 5).

2-Benzyloxy-3,3-dimethyl-4-acetoxy butyric acid (15)

To a solution of 5.0 g (0.018 moles) of 2-benzyloxy-3,3-dimethyl-4-acetoxy butyramide in 25 ml of glacial acetic acid was added 9 ml of isoamyl nitrite (Eastman). The mixture was heated at reflux for 40 min, 3 ml of isoamyl nitrite were added and the heating continued for an additional hour. The solution was cooled and the volatile material removed on the rotary evaporator in vacuo. Water was added to the residue, and the mixture was made alkaline with 1N sodium hydroxide solution. After extracting with chloroform, the aqueous layer was acidified with dilute (15%) hydrochloric acid and again extracted with chloroform. This extract was washed, dried and evaporated. The residue dissolved in sodium bicarbonate solution and repurified in the same way gave 2.5 g (50% yield) of red-orange oil. Anal. Calcd for C₁₅H₂₀O₅: C, 64.27; H, 7.18. Found: C, 64.16; H, 7.20.

Nmr spectrum (CDCl₃): 1.05 (singlet, area 6), 1.96 (singlet, 3), 3.85 (singlet, 1), 3.86, 4.05 (doublet, J = 10, 2), 4.35, 4.73 (doublet, J = 11, 2), 7.38 (singlet, 5), 10.06 (singlet, 1, D₂O exchange).

2-Benzyloxy-3,3-dimethyl-4-acetoxy-N-[4-(2-pyrimidinylaminosulfonyl)-phenyl]butyramide (AD 88955)

15.0 g (0.054 moles) of 2-benzyloxy-3,3-dimethyl-4-acetoxy butyric acid were combined with 32 ml of thionyl chloride and heated on the steam bath for 1 hr. After cooling, the excess thionyl chloride was removed in vacuo. The residue was dissolved in benzene (500 ml) and added slowly with cooling to a pyridine solution (250 ml) of 13.2 g (0.053 moles) sulfadiazine. The reaction mixture was stirred overnight at

room temperature and heated for 4 hr on the steam bath. After cooling, the solvents were removed on the rotary evaporator. The residue was treated with water and extracted with chloroform. The extract was washed, dried and evaporated to give 22 g of brown gum. The gum was chromatographed on silicic acid (100 mesh) and eluted with chloroform. Recrystallization from ethyl acetate/petroleum ether gave 4.95 g (19%) white powder, mp 161-163°.

Anal. Calcd for $C_{25}H_{28}N_4O_6S$: C, 58.59; H, 5.51; N, 10.93. Found: C, 58.85; H, 5.58; N, 10.89.

The amide showed an ultraviolet adsorption band at λ_{\max}^{EtOH} 263 m μ (log ϵ 4.45) and infrared bands (KBr) at 1735, 1690, 1160 cm^{-1} . Nmr spectrum ($CDCl_3$): 1.03, 1.06 (singlets, area 6), 1.9 (singlet, 3), 3.94 (multiplet, 3), 4.57 (singlet, 2), 6.98 (triplet, $J = 5, 1$), 7.23 (singlet, 5), 7.68 (doublet, $J = 8.5, 2$), 8.04 (doublet, $J = 8.5, 2$), 8.64 (doublet, $J = 5, 2$), 8.71 (singlet, 1), 10.16 (broad, 1, D_2O exchange).

A 0.5 g sample (15337-51) was submitted on May 29, 1968, for testing in the WRAIR malaria screen.

4-Acetoxy-2-benzyloxy-3,3-dimethyl-4'-fluorosulfonylbutyranilide (AS 34792)

6.0 g (0.021 mole) of 2-benzyloxy-3,3-dimethyl-4-acetoxybutyric acid (15) was reacted with 3.75 g (0.021 mole) of sulfanilyl fluoride according to the method of Baker.¹⁹ The starting materials were added to xylene and the mixture was refluxed for 5 hours. Hydrogen chloride was evolved and the solvent was allowed to distill slowly. The remaining solution was concentrated to a dark brown oil. Ether was added to the residue, the solution was cooled and a dark brown solid crystallized. Additional solid was obtained from the mother liquor by the same procedure. Two recrystallizations from methylene chloride/n-hexane gave 1.20 g (13%) white solid, mp 93-97°.

Anal. Calcd for $C_{21}H_{24}FN_6O_6S$: C, 57.66; H, 5.53; N, 3.20. Found: C, 57.46; H, 5.54; N, 3.26.

The compound showed an ultraviolet absorption band at λ_{\max}^{EtOH} 265 m μ (log ϵ 4.35) and infrared bands (KBr) at 3300, 1715 and 1690 cm^{-1} .

A 1.15 g sample (15337-70) was submitted on December 2, 1968, for testing in the WRAIR malaria screen.

4-Acetoxy-2-benzyloxy-3,3-dimethyl-N-(1H-1,2,4-triazol-3-yl)butyramide (AS 34818)

6.0 g (0.021 mole) of 2-benzyloxy-3,3-dimethyl-4-acetoxybutyric acid (15) and 20 ml of thionyl chloride were combined and heated on the steam bath for one half hour. The excess thionyl chloride was removed on the rotary evaporator, and finally in vacuo. A solution of 1.8 g (0.021 mole) of 3-amino-1,2,4-triazole in 100 ml of pyridine was added

with stirring and cooling to the acid chloride. After stirring overnight at room temperature, the pyridine was removed. The residue was added to water and extracted with chloroform. The extract was washed with sodium bicarbonate solution and water, dried over sodium sulfate and evaporated to give a dark oil. The oil was chromatographed using Florisil (60-100 mesh) and methanol/chloroform to elute. The desired compound was obtained as a yellow oil from the 5% methanol/chloroform fractions. The oil was crystallized several times from chloroform/n-hexane to give 0.6 g (9%) colorless crystals, mp 106-107°.

Anal. Calcd for $C_{17}H_{22}N_4O_4$: C, 58.95; H, 6.40; N, 16.17. Found: C, 58.83; H, 6.45; N, 16.28.

The compound showed an ultraviolet absorption band at $\lambda_{\max}^{\text{EtOH}}$ 265 m μ (log ϵ 3.63) and infrared bands (KBr) at 3460, 1735, 1720 and 1635 cm^{-1} .

A 0.6 g sample (15337-72) was submitted for testing in the WRAIR malaria screen.

4-Acetoxy-N-(2-benzimidazolyl)-2-benzyloxy-3,3-dimethylbutyramide (AT 14982)

6.0 g (0.021 mole) of 2-benzyloxy-3,3-dimethyl-4-acetoxybutyric acid was combined with 20 ml of thionyl chloride and heated on the steam bath for one half hour. The excess thionyl chloride was removed on the rotary evaporator and finally in vacuo. A pyridine solution of 2-amino-benzimidazole (3.0 g, 0.022 mole) was added to the acid chloride with cooling and stirring. The mixture was stirred overnight at room temperature and the pyridine was removed on the rotary evaporator. Water was added to the residue and the mixture was extracted with ethyl acetate. The extract was washed with saturated sodium bicarbonate solution, water, dried over sodium sulfate and evaporated. The oily residue was dissolved in a small quantity of ether and cooled to give crystals. Recrystallization from methylene chloride/n-hexane gave 0.6 g (8%) of colorless crystals, mp 161-163°.

Anal. Calcd for $C_{22}H_{25}N_3O_4$: C, 66.82; H, 6.37; N, 10.62. Found: C, 66.74; H, 6.26; N, 10.54.

The amide showed ultraviolet adsorption bands at $\lambda_{\max}^{\text{EtOH}}$ 285 m μ (log ϵ 4.23), 292 m μ (log ϵ 4.20) and 250 m μ (log ϵ 3.98) and infrared bands (KBr) at 3270, 1745, 1685 and 1625 cm^{-1} .

A 0.6 g sample (15897-2) was submitted on February 4, 1969, for testing in the WRAIR malaria screen.

2-Benzyloxy-3,3-dimethyl-4-hydroxy-N-[4-(2-pyrimidinylaminosulfonyl)-phenyl]butyramide (AD 88964)

To a mixture of 4.45 g of 2-benzyloxy-3,3-dimethyl-4-acetoxy-N-[4-(2-pyrimidinylaminosulfonyl)phenyl]butyramide (AD 88955, 0.0087 moles) in 200 ml water and 225 ml methanol was added 19.5 ml of 1N NaOH solution (0.0195 moles). The solution was stirred at room temperature for 1 1/2 hr and neutralized with dilute (15%) hydrochloric acid. White solid appeared after neutralization and during the removal of methanol on the rotary evaporator. The desired compound was extracted into chloroform from the remaining aqueous fraction. The extract was washed, dried and evaporated to give a colorless, viscous oil. Trituration with ethyl ether and filtration gave 3.90 g (95%) of white powder, mp 170-172°. Anal. Calcd for C₂₃H₂₆N₄O₅S: C, 58.71; H, 5.57; N, 11.91. Found: C, 58.79; H, 5.69; N, 11.98.

The compound showed an ultraviolet adsorption band at $\lambda_{\text{max}}^{\text{EtOH}}$ 263 m μ (log ϵ 4.42) and infrared bands (KBr) at 3500, 1680, 1155 cm⁻¹. Nmr spectrum (pyridine d₅): 1.2, 1.23 (singlets, area 6), 3.74 (singlet, 2), 4.32 (singlet, 1), 4.54 (doublet, J = 11, 1), 4.74 (doublet, J = 11, 1), 6.65 (triplet, J = 5, 1), 7.2 (multiplet, 5), 8.03, 8.38 (doublets, J = 8.5, 4), 8.35 (doublet, J = 5, 2), 9.5 (broad, 1, D₂O exchange), 10.15 (singlet, 1, D₂O exchange).

A 1.0 g sample (15337-53) was submitted on May 29, 1968, for testing in the WRAIR malaria screen.

2-Benzyloxy-3,3-dimethyl-4-hydroxy-N-(6-methoxy-8-quinolyl)butyramide (AE 86554)

12.0 g (0.043 moles) of 2-benzyloxy-3,3-dimethyl-4-acetoxybutyric acid (15) and 20 ml of thionyl chloride were combined and heated on the steam bath for one hour. The excess thionyl chloride was removed on the rotary evaporator. A solution of 7.5 g (0.043 moles) of 8-amino-6-methoxyquinoline in 140 ml of pyridine was added with stirring and cooling to the acid chloride. After stirring overnight at room temperature the pyridine was removed. The residue was added to water and extracted with chloroform. The extract was washed, dried and evaporated to give 22 grams of black oil. The product was purified by chromatography on silicic acid (100 mesh) using 2% ethyl acetate/chloroform. 7.7 grams of orange-brown oil were obtained (41% yield). The structure was confirmed by nmr and IR.

To a solution of 7.7 g (0.0176 moles) of 2-benzyloxy-3,3-dimethyl-4-acetoxy-N-(6-methoxy-8-quinolyl)butyramide in 300 ml of methanol was added 26.5 ml of 1N sodium hydroxide solution (0.0265 moles). The solution was stirred at room temperature for 1 1/2 hours. After neutralization with dilute (15%) hydrochloric acid, the methanol was removed on a rotary evaporator. The residue was treated with water and extracted with chloroform. This extract was washed, dried and evaporated to give 6.0 g orange oil. The oil was chromatographed on silicic acid (100 mesh) using increasing quantities of chloroform in benzene. The material was obtained as dark red crystals from the 1 benzene:4 chloroform fractions. Several recrystallizations from methylene chloride/n-hexane gave 1.25 g (18%) of white crystals, mp 105-107°.

Anal. Calcd for $C_{23}H_{26}N_2O_4$: C, 70.03; H, 6.64; N, 7.10. Found: C, 70.01; H, 6.51; N, 7.03.

The amide showed ultraviolet absorption bands at $\lambda_{\max}^{\text{EtOH}}$ 335 m μ (log ϵ 3.81), 305 m μ (log ϵ 3.72), 244 m μ (log ϵ 4.77) and 215 m μ (log ϵ 4.51), and infrared bands at 3475 and 1660 cm^{-1} .

A 0.75 g sample (15337-60) was submitted on August 1, 1968, for testing in the WRAIR malaria screen.

2-Benzyloxy-3,3-dimethyl-4-hydroxy-4'-[(3-methoxy-2-pyrazinyl)aminosulfonyl]butyranilide (AF 14571)

4.3 g (0.015 mole) of 2-benzyloxy-3,3-dimethyl-4-acetoxybutyric acid (15) and 10 ml of thionyl chloride were combined and heated on the steam bath for one half hour. The excess thionyl chloride was removed on the rotary evaporator. The residue was dissolved in benzene (150 ml) and added slowly and with cooling to a pyridine solution (75 ml) of 3-methoxy-2-sulfanilamidopyrazine (4.15 g, 0.0148 mole). After stirring overnight at room temperature the reaction mixture was heated on the steam bath for four hours. The solvents were removed on the rotary evaporator. Water was added to the residue and the mixture was extracted with chloroform. The extract was washed with dilute hydrochloric acid, sodium bicarbonate solution and water. After drying over sodium sulphate the solvent was evaporated to give 6.5 g of dark red-brown oil. The structure was confirmed by IR.

To a solution of 6.5 g of 4-acetoxy-2-benzyloxy-3,3-dimethyl-4'-[(3-methoxy-2-pyrazinyl)aminosulfonyl]butyranilide in 250 ml of water and 300 ml of methanol was added an excess of sodium hydroxide (30.0 ml 1N solution). The mixture was stirred at room temperature for 3 hours. After neutralization with dilute hydrochloric acid, methanol was removed on the rotary evaporator. The aqueous residue was shaken with chloroform, and the extract was washed, dried and evaporated to give 4.9 g red oil. A chloroform solution of the oil was chromatographed through silicic acid (100 mesh) and eluted with 5% methanol/chloroform. One fraction gave a single spot in tlc, although analysis showed the sample

to be impure. The sample was dissolved in ethyl acetate and treated with charcoal (Norite A). The solution was washed with sodium bicarbonate solution and water and dried over sodium sulfate. Evaporation of the solvent left 0.65 g pale yellow oil which became foamy after drying in vacuo. An additional 0.3 g sample (slightly impure by tlc) was obtained. Anal. Calcd for C₂₄H₂₈N₄O₆S: C, 57.59; H, 5.64; N, 11.19. Found: C, 56.55; H, 5.66; N, 11.19.

The amide showed an ultraviolet band at $\lambda_{\max}^{\text{EtOH}}$ 260 m μ (log ϵ 4.31) and infrared bands (KBr) at 3500 (broad) 3370 and 1680 cm⁻¹. Nmr (CDCl₃) 0.94, 1.06 (singlet, area 6), 3.48 (s, 2), 3.95 (s, 3), 4.63 (s, 2), 7.36 (s, 5), 7.66 (doublet, J = 9, 2), 8.11 (d, J = 9, 2), 7.66 (s, 2).

This information indicated the correct structure, although the sample was somewhat impure by analysis. The 0.65 g sample (15337-62) was submitted on September 30, 1968, for testing in the WRAIR malaria screen.

2-Benzoyloxy-3,3-dimethyl-4'-[(5,6-Dimethoxy-4-pyrimidinyl)aminosulfonyl]-4-hydroxybutyranilide (AE 96096)

4.5 g (0.016 moles) of 2-benzoyloxy-3,3-dimethyl-4-acetoxybutyric acid (15) and 10 ml of thionyl chloride were combined and heated on the steam bath for one hour. The excess thionyl chloride was removed on the rotary evaporator. The residue was dissolved in 150 ml of benzene and added with cooling and stirring to a pyridine solution (75 ml) of 5,6-dimethoxy-4-sulfanilamidopyrimidine (4.65 g, 0.015 moles). The mixture was ~~stirred~~ overnight at room temperature and heated on the steam bath for ~~one~~ hours. The solvents were removed on the rotary evaporator, and ~~the residue~~ was added to the residue. The compound was taken up in chloroform, and the extract was washed with dilute hydrochloric acid, sodium bicarbonate solution and dried over sodium sulfate. Evaporation of the chloroform left 8.7 g of red-yellow oil. The structure of the compound was confirmed by IR (CHCl₃) although the sample was somewhat impure (see in 10% MeOH/CHCl₃).

To a mixture of 8.7 g of 2-benzoyloxy-3,3-dimethyl-4'-[(5,6-dimethoxy-4-pyrimidinyl)aminosulfonyl]-4-acetoxybutyranilide in 300 ml water and 350 ml methanol was added 38.0 ml of 1N sodium hydroxide solution. The solution was stirred at room temperature for 1 1/2 hr and neutralized with dilute (15%) hydrochloric acid. The methanol was removed on the rotary evaporator and the remaining aqueous fraction was extracted with chloroform. The extract was washed, dried and evaporated to give 7.4 g of red-yellow oil. The oil was chromatographed using silicic acid (100 mesh) and chloroform. The compound was obtained as 3.6 g (43%) of yellow oil which changed to powdery foam after considerable drying in vacuo.

Anal. Calcd for C₂₅H₃₀N₄O₇S: C, 56.60; H, 5.70; N, 10.56. Found: C, 56.53; H, 5.69; N, 10.38.

The amide showed an ultraviolet absorption band at $\lambda_{\text{max}}^{\text{EtOH}}$ 265 m μ (ϵ 4.43) and infrared bands at 3475 and 1680 cm^{-1} .

A 2.0 g sample (15337-63) was submitted on August 30, 1968, for testing in the WRAIR malaria screen.

Dibenzyl p-bromoanilinephosphonate (AE 48983)

7.8 g (0.03 mole) of dibenzylphosphonate¹⁶ was dissolved in 30 ml of dry benzene and (4.06 g; ca 0.03 mole) of N-chlorosuccinimide was added in small lots. The reaction mixture warmed up and was stirred at room temperature for 2 hr. Succinimide that had separated out was filtered through a sintered glass funnel and to the filtrate (10.32 g; 0.06 mole) of p-bromoaniline was added and the reaction mixture stirred for 4 hr. Amine hydrochloride that had precipitated was filtered and washed with hot benzene. The filtrate was washed with 50 ml of 1N HCl followed by aqueous NaHCO_3 and saturated sodium chloride solution and dried over anhydrous sodium sulfate. Removal of the solvent on the rotary evaporator gave an oily residue which on leaving in contact with methylene chloride and n-hexane solidified. After crystallization from methylene chloride and n-hexane twice analytically pure sample (1 g), mp 85-87°, was obtained.

Anal. Calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}_3\text{P}$: C, 55.54; H, 4.40; N, 3.24. Found: C, 55.36; H, 4.31; N, 3.20.

A 0.4 g sample (15458-12) was submitted on July 1, 1968, for testing in the WRAIR malaria screen.

Dibenzyl p-methoxyanilinephosphonate (AE 48974)

5.24 g (0.02 mole) of dibenzyl phosphonate¹⁶ was dissolved in 20 ml of dry benzene and (2.67 g; 0.02 mole) of N-chlorosuccinimide was added in small lots. The reaction mixture was stirred at room temperature for 2 hr. Succinimide that had separated out was filtered through a sintered glass funnel and to the filtrate 4.92 g (0.04 mole) of p-methoxyaniline was added and the mixture stirred for 4 hr. Amine hydrochloride that had precipitated out was filtered and washed with hot benzene. The filtrate was washed with 50 ml of 1N HCl followed by aq NaHCO_3 and saturated sodium chloride solution and dried over anhydrous sodium sulfate. Removal of the solvent on the rotary evaporator gave an oily residue which on leaving in contact with methylene chloride and n-hexane solidified. After crystallization from methylene chloride and n-hexane analytically pure sample (2.82 g), mp 115-117°, was obtained.

Anal. Calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_4\text{P}$: C, 65.80; H, 5.74; N, 3.65. Found: C, 65.68; H, 5.68; N, 3.59.

A 1.0 g sample (15458-13) was submitted on July 1, 1968, for testing in the WRAIR malaria screen.

Dibenzyl benzylaminephosphonate²⁰ (AE 48965)

5.24 g (0.02 mole) of dibenzylphosphonate was dissolved in 20 ml of dry benzene and (2.67 g; 0.02 mole) of N-chlorosuccinimide was added in small lots. The reaction mixture was stirred at room temperature for 2 hr. Succinimide that had separated out was filtered through a sintered glass funnel and to the filtrate (4.28 g; 0.04 mole) of benzylamine in 30 ml of dry benzene was added and the mixture stirred for 4 hr. Amine hydrochloride that had separated out was filtered and washed with hot benzene. The filtrate was washed with 50 ml of 1N HCl followed by aq NaHCO₃ and saturated sodium chloride solution and dried over anhydrous sodium sulfate. Removal of the solvent on the rotary evaporator gave a thick syrupy residue which on leaving in contact with methylene chloride and n-hexane solidified. After crystallization from methylene chloride and n-hexane, 3.27 g of a white crystalline solid, mp 82-85°, was obtained (lit.²⁰ mp 84-85°).

A 1.0 g sample (15458-14) was submitted on July 1, 1968, for testing in the WRAIR malaria screen.

Dibenzyl N-cyclohexylphosphoramidate²⁰ (AS 34774)

5.24 g (0.02 mole of dibenzylphosphonate¹⁶ was dissolved in 20 ml of dry benzene and 2.67 g (0.02 mole) of N-chlorosuccinimide was added in small lots. The reaction mixture was stirred at room temperature for 2 hr. Succinimide that had separated out was filtered through a sintered glass funnel and to the filtrate 3.96 g (0.04 mole) of cyclohexylamine in 30 ml of dry benzene was added and the mixture stirred for 4 hr. Amine hydrochloride that had separated out was filtered and washed with hot benzene. The filtrate was washed with 50 ml of 1N HCl followed by aq NaHCO₃ and saturated sodium chloride solution and dried over anhydrous sodium sulfate. Removal of the solvent on the rotary evaporator gave a thick syrupy residue which on leaving in contact with methylene chloride and n-hexane solidified. After crystallization from methylene chloride and n-hexane 2.1 g of a white crystalline solid, mp 77-78°, was obtained (lit.²⁰ mp 79-80°).

A 2.1 g sample (15458-18) was submitted on December 2, 1968, for testing in the WRAIR malaria screen.

N¹-2-(3,4,5,6-Tetrahydropyrimidinyl)sulfanilamide (AE 86545)

To 3.0 g of sulfathiazine (0.012 moles) in 250 ml of methanol and 12.0 ml of 1N sodium hydroxide solution was added 1.2 g of 10% Palladium on Charcoal (Engelhardt). The mixture was hydrogenated at atmospheric pressure; the retical uptake of hydrogen required 2.5 hours. The reaction mixture was filtered and the filtrate was concentrated to a volume of 50 ml. White, crystalline solid was obtained. The material was recrystallized by dissolving (with heating) in a large volume of methanol, reducing the volume to one-half and cooling. Yield of white crystals was 0.55 g (9%), mp 2.3-2.5°.

Anal. Calcd for C₁₀H₁₃N₄O₂S: C, 47.43; H, 5.17; N, 22.21. Found: C, 47.31; H, 5.46; N, 22.22.

The compound showed an ultraviolet absorption band at $\lambda_{\max}^{\text{EtOH}}$ 264 m μ (log ϵ 4.28) and infrared bands (KBr) at 3480, 1620, 1590, 1370, 1175 cm⁻¹. Nmr spectrum (DMSO d₆) 1.64 multiplet, area 2), 3.1 (multiplet 4), 5.46 (singlet, 2 D₂O exchange), 6.47 (doublet, 4, J = 9 cps), 7.29 (doublet, 4, J = 9 cps), 7.3 (2, D₂O exchange).

A 0.55 g sample (15337-58) was submitted on July 30, 1968, for testing in the WRAIR malaria screen.

LITERATURE CITED

1. W. Trager, J. Exptl. Med., 77, 411 (1943).
2. D. W. Woolley, Science, 100, 579 (1944); D. W. Woolley and M. L. Collyer, J. Biol. Chem., 159, 263 (1945).
3. R. E. Lutz, J. W. Wilson, A. J. Deinet, G. H. Harnest, T. A. Martin, and J. A. Freek, J. Org. Chem., 12, 96 (1947).
4. R. Winterbottom, J. W. Clapp, W. H. Miller, J. P. English, and R. O. Roblin, J. Am. Chem. Soc., 69, 1393 (1947).
5. A. E. Snear, M. M. Rapport and J. B. Koepfli, J. Biol. Chem., 167, 229 (1947).
6. W. Drell and M. S. Dunn, J. Am. Chem. Soc., (a) 68, 368 (1946); (b) 70, 2058 (1948); (c) 76, 2804 (1954).
7. W. Trager, Trans. N. Y. Acad. of Sciences, 28, 1094 (1966).
8. For a detailed discussion, see Annual Reports (a) March 1, 1967, p. 13 and (b) March 1, 1963, p. 8 of Contract DA-49-193-MD-2879.
9. W. Shive and I. Z. Snell, J. Biol. Chem., 160, 287 (1945).
10. Personal communication from Dr. Poon of WRAIR.
11. Survey of Antimalarial Drugs, F. Y. Wiselogle, ed., J. W. Edwards, Ann Arbor, Michigan, 1946, Vol. I, p. 174. For a discussion on antipantothenes, see p. 138.
12. S. Brackett, E. Waletzky, and M. Baker, J. Parasitol., 32, 453 (1946).
13. Personal communication from Dr. Strube and Dr. Poon of WRAIR.
14. Reference 11, p. 491; test procedure 0-1.
15. S. S. G. Sircar, J. Chem. Soc., 901 (1928).
16. O. I. Friedman, D. L. Klass and A. M. Seligman, J. Am. Chem. Soc. 76, 916 (1954).
17. G. W. Kenner, A. R. Todd and F. J. Weymouth, J. Chem. Soc. 3675 (1952).
18. J. Baddiley and E. M. Thain, J. Chem. Soc., 249 (1951).
19. B. R. Baker and G. H. Laurens, J. Med. Chem., 10, 1118 (1967).
20. F. R. Atherton, H. T. Openshaw and A. R. Todd, J. Chem. Soc., 384 (1945).

Security Classification

DOCUMENT CONTROL DATA - R & D

(Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified)

1. ORIGINATING ACTIVITY (Corporate author) Arthur D. Little, Inc. Cambridge, Massachusetts 02140		2a. REPORT SECURITY CLASSIFICATION Unclassified	
		2b. GROUP —	
3. REPORT TITLE The Synthesis of New Antimalarial Drugs Analog of Pantothenic Acid			
4. DESCRIPTIVE NOTES (Type of report and inclusive dates) Final report combined with Annual Report 3, March 1, 1968 thru March 31, 1969			
5. AUTHOR(S) (First name, middle initial, last name) Raj K. Razdan Barbara A. Zitko Avinash C. Mehta			
6. REPORT DATE 31 March 1969	7a. TOTAL NO. OF PAGES 92	7b. NO. OF REFS 20	
8a. CONTRACT OR GRANT NO. DA-49-193-MD-2879	8b. ORIGINATOR'S REPORT NUMBER 68066		
8c. PROJECT NO.	8d. OTHER REPORT NUM (Any other numbers that may be assigned this report) —		
9. DISTRIBUTION STATEMENT Distribution of this document is unlimited.			
11. SUPPLEMENTARY NOTES Antimalarials	12. SPONSORING MILITARY ACTIVITY U.S. Army Medical Research & Development Command (B. Poon, Proj. Washington, D. C. 20315 Officer)		
13. ABSTRACT The present synthetic program on antagonists of pantothenic acid was based on the demonstrated antimalarial activity of SN 14622. (WR 29,224) in avian malaria from World War II program. During the three years of our work we have prepared and submitted for evaluation one hundred and eight compounds. Unfortunately, SN 14622 is completely inactive in the present WRAIR screens in mice, chicks and mosquitoes. It appears that the nonproducibility of the activity of SN 14622 in the present chick screen is due to the different test procedure being used. A few of our compounds were tested in Dr. Trager's <u>in vitro</u> screen and of these WR 54036 has been selected for advanced screening in the monkey. Three other compounds, WR 61467, AE 96096 and AF 14571 (derivatives of sulfonamides) have been found to be active in the Rame screen in mice at 160, 40, and 160 mg/kg respectively.			

Security Classification

14. KEY WORDS	LINK A		LINK B		LINK C	
	ROLE	WT	ROLE	WT	ROLE	WT
Antimalarials						
Pantothenic acid antagonists						
Biological activity						
Sulfadiazine derivatives						
Fanasil derivatives						
Kelfizina derivatives						
Phenylpantothenones						
ω -Methylpantoyltaurines						
Pantoyltaurines						
2-Amino-N-substituted sulfonamides						
Phthalimides						
ω -Methylpantoylsulfones						
Pantoylsulfones						
Pantoic acid derivatives						
Organic Synthesis						
Rane mice screen						
Rane bird screen						
Mosquito screen						